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Abstract

SIGNS AND SYMPTOMS OF OPIOID WITHDRAWAL IN THE PEDIATRIC PATIENT
DURING OPIOID TAPERING

By Deborah Fisher, PhD, RN, CS, PNP-BC, CPON

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2012

VCU Chair: Mary Jo Grap, PhD, RN, FAAN
Professor, Adult Health and Nursing Systems
School of Nursing

Opioids are used routinely in the pediatric intensive care population for
analgesia, sedation, blunting of physiologic responses to stress, and safety. In children,
physical dependence may occur in as little as two to three days of continuous opioid
therapy. Once the child no longer needs the opioid, the medications are reduced over
time. A review of the literature revealed that the majority of the published studies used
either a neonatal opioid assessment tool or no assessment tool. A subsequent
international survey of pediatric providers found a wide range of opioid tapering
practices and sporadic use of opioid withdrawal instruments to guide practice. Since
tapering routines vary among practitioners, it is not uncommon to see signs and

symptoms of opioid withdrawal. A prospective, descriptive study was conducted to
describe the frequency of opioid withdrawal signs and symptoms and to identify factors
associated with these opioid withdrawal signs and symptoms. The sample of 25 was
drawn from all patients, ages 2 weeks to 21 years admitted to the Children’s Hospital of
Richmond Pediatric Intensive Care Unit (PICU) and who have received continuous
infusion or scheduled opioids for at least 5 days. Data collected included: opioid
withdrawal score (WAT-1), opioid taper rate (total dose of opioid per day in morphine
equivalents per kilogram [MEK]), pretaper peak MEK, pretaper cumulative MEK,
number of days of opioid exposure prior to taper, and age. Out of 26 enrolled
participants, only 9 (45%) had opioid withdrawal on any given day. In addition, there
was limited variability in WAT-1 scores. The most common symptoms notes were
diarrhea, vomit, sweat, and fever. For optimal opioid withdrawal assessments, clinicians
should use a validated instrument such as the WAT-1 to measure for signs and
symptoms of opioid withdrawal. Further research is indicated to examine risk factors for
opioid withdrawal in children.

Key Words: opioid withdrawal, opioid taper, opioid analgesia, critical care, child

CHAPTER 1. INTRODUCTION

Background and Significance
Opioids are used routinely in the pediatric intensive care population for
analgesia, sedation, blunting of physiologic responses to stress, and safety. 1-3 The
therapeutic goal of providing adequate analgesia and sedation often results in days to
weeks of continuous exposure to opioids and sedative. Continued exposure may lead to
iatrogenic opioid dependence. Opioid dependence is defined as a state of adaptation
that is manifested by a drug class specific withdrawal syndrome that can be produced
by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or
administration of an antagonist. 4 Opioid withdrawal is a clinical response to the
cessation of an opioid after continuous, prolonged exposure to that opioid. 5 Therefore, it
is clinically and ethically prudent to taper opioids in a safe manner with a goal of
avoidance of opioid withdrawal.
Presently, there is no gold standard for opioid tapering in children. A review of
the literature of the empiric evidence to guide opioid tapering while avoiding opioid
withdrawal in children is presented in Chapter 2.6
The majority of published research has focused on the periodic incidence of
withdrawal symptoms during opioid tapering. Only recently has a valid and reliable
pediatric opioid withdrawal symptom assessment instrument- the Withdrawal
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Assessment Tool (WAT-1)7 been developed and this tool is reviewed in Chapter 2. In
addition, only one study conducted in an adult and pediatric population analyzed the
effect of use of an opioid taper algorithm on occurrence and nature of opioid withdrawal
symptoms. Once clinicians can recognize risk factors for opioid withdrawal and can
appropriately assess their patients using a validated opioid withdrawal instrument, the
goal of tapering an opioid properly while avoiding opioid withdrawal is possible.
Although the WAT-1 was published in 20087, except for the initial and
subsequent validation studies for the WAT-1, no studies have been conducted using a
validated pediatric opioid withdrawal assessment tool to describe the frequency of
opioid withdrawal as well as factors that affect the frequency. Since little information is
known about opioid withdrawal in a pediatric population, a study describing the
frequency of opioid withdrawal signs and symptoms and to identify factors associated
with opioid withdrawal is presented in Chapter 3.
A prospective, longitudinal descriptive study was initiated to explore the
frequency of opioid withdrawal and detect associated risk factors in a pediatric
population. The specific aims of this study were to: (1) describe the signs and symptoms
of opioid withdrawal in children undergoing opioid tapering; and (2) examine the
relationship among opioid withdrawal signs and symptoms, opioid exposure (cumulative
opioid dose, peak opioid dose, duration of opioid exposure), opioid taper rate and the
child’s age. Permission for inclusion in the study was obtained from parents or legal
guardians. Twenty six participants were enrolled. Demographic data was collected to
describe the sample. To identify opioid withdrawal signs and symptoms, the WAT-17
was used daily. Opioid exposure prior to study enrollment was calculated and all opioids
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converted to morphine equivalents. Each day’s previous twenty-four hours opioid
exposure was calculated and converted to morphine equivalents per kilogram (MEK).
All participants were assessed for opioid withdrawal daily for up to 7 days. Participant
characteristics were examined for possible association with opioid withdrawal.
On any given day, opioid withdrawal was noted in half (n=12) of the participants.
The most common signs of opioid withdrawal were diarrhea, vomiting, sweating and
fever. Of those participants who had opioid withdrawal, the level of severity, based on
WAT-1 scores, was not severe. In addition, for those patients with opioid withdrawal, the
effect of previously reported risk factors was examined. There was no relationship
between peak opioid dose and opioid withdrawal. We found a relationship between
opioid duration and withdrawal that approached significance (r=0.36; p-value>0.07),
showing that as opioid duration increased, opioid withdrawal increased. In addition, as
cumulative opioid dose increased, withdrawal increased (r=33; p>0.09).
This study contributes new knowledge to the description of signs and symptoms
of opioid withdrawal in the pediatric patient undergoing opioid tapering. We believe this
is the first study to be conducted using the WAT-1 to measure signs and symptoms of
opioid withdrawal in children. The investigators who developed and validated the WAT-1
found that opioid duration and cumulative dose were predictors of risk of opioid
withdrawal. In conjunction with the evidence reported by the investigators who
developed and validated the WAT-1 scale, this evidence should inform clinicians of the
potential risk factors as well as signs and symptoms of opioid withdrawal in children.
Improvements in opioid management may lead to higher patient satisfaction, decreased
length of stay and decreased suffering.
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CHAPTER 2. OPIOID TAPERING IN CHILDREN:
A REVIEW OF THE LITERATURE

Background
Routine sedation and analgesia for ventilated children in the intensive care unit is
standard practice. Unfortunately, the therapeutic goal of providing adequate analgesia
and sedation often results in days to weeks of continuous exposure to opioids and
sedatives. Continuous exposure results in iatrogenic opioid and sedative dependence.
In children, physical dependence has been found to occur in as little as two to three
days of continuous opioid therapy.1 Tolerance to opioids has been seen to develop
even more rapidly in neonates and infants.2 Once the child no longer needs the opioid
or sedatives, the medications are weaned. Since tapering routines vary among
practitioners, it is not uncommon for nurses to witness symptoms of opioid withdrawal in
this vulnerable population. Opioid withdrawal symptoms include hiccups, goose bumps,
chills, fever, tachycardia, tachypnea, hypertension, agitation, restlessness, insomnia,
nausea, vomiting, diarrhea, cramps, lacrimation, rhinorrhea, yawning, diaphoresis,
mydriasis, bone pain, muscle aches and spasms, and seizures.1 Acute effects of
withdrawal symptoms are numerous. Diarrhea and vomiting can lead to dehydration.
Tachycardia may lead to unnecessary IV fluid boluses or even cardiology evaluations.
Routine use of validated opioid withdrawal assessment tools or algorithms is rare, which
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contributes to delays in diagnosis of opioid withdrawal syndrome and proper treatment.
Potential long term effects of poorly managed withdrawal symptoms are unknown;
however, possible consequences include prolonged tapering duration in response to
attempts to alleviate withdrawal symptoms as well as needless physical and emotional
suffering. Of note, only one position statement on drug withdrawal was discovered
during the search. The American Academy of Pediatrics (AAP) has a position statement
on neonatal drug withdrawal with recommendations that include multimodal maternal
screening for opioid use, enhanced recognition of signs of opioid withdrawal, routine
use of appropriate opioid withdrawal tools, and medication recommendations for opioid
or sedative withdrawal.3 However, no such statement exists for the pediatric population.
The purpose of this critical review of the literature was to synthesize and critically
analyze published research and other critical reviews on opioid withdrawal management
in children.
METHODS
A search of the major databases for English language publications included
Cochrane, MEDLINE, CINAHL and PsychInfo. Keywords used included: “opioid”,
“withdrawal”, “abstinence”, “infant” and “child” (n=114). The resulting group was then
limited to 1980-2009 (n=93). Age limits were set at one month to eighteen years of age.
Even though there is a wealth of information regarding opioid abstinence syndrome in
neonates, studies pertaining to premature neonates or infants born to mothers on
opioids were excluded due to the neurodevelopmental differences in manifestations of
opioid abstinence syndrome. Two articles were excluded since they were inaccessible.
The remaining articles were reviewed for relevance to the purpose of the review (n=20).
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Articles were included if the focus remained on a pediatric population undergoing opioid
tapering. Due to the relatively small sample size, articles that included a mix of pediatric
patients and adult patients were included. Opinions, editorials and individual case
studies were not included. In addition, articles that studied the efficacy of a prophylactic
pharmaceutical intervention were excluded. The remaining articles were assessed for
inclusion criteria. Thirteen papers met the criteria for review.
DATA COLLECTION AND ANALYSIS
Once accepted for review, the main aspects of each article were extracted and
summarized in table format. These thirteen papers were categorized into five groups
determined by the main focus of the research: opioid tolerance in children (n=1);
incidence of opioid withdrawal (n=6); review articles (n=2); use of algorithm or protocol
(n=1); validation of assessment tools in pediatric population (n=3). The table was further
delineated into five columns: year, authors, sample, design and key findings. (See Table
1) Conclusions from each of the articles were reviewed and examined for emerging
themes. Upon completion of tabulation, findings were reviewed and assessed for
correlations and similarities.
RESULTS
Opioid tolerance in children. Only one study was found that reviewed opioid
tolerance in children and infants.4 Scales reviewed were all validated in neonatal
populations. The authors concluded that opioid withdrawal could be avoided with the
use of appropriate tapering protocols and assessment tools. Should signs of withdrawal
occur, pharmacological and non-pharmacological interventions were suggested. Nonpharmacological intervention suggestions included rocking, swaddling, reduced
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environmental stimulation and frequent feedings. Pharmacological recommendations for
length of taper correlated with length of exposure to opioids. Specifically, if opioid
exposure was less than one week, tapering could occur over three days. For infants
exposed to over one week of opioids, a less aggressive protocol, tapering over two to
three weeks, was recommended.
Opioid withdrawal symptoms in children. Six studies examined the incidence of
opioid withdrawal symptoms in children undergoing opioid taper. All but one of the
studies was conducted in a pediatric intensive care unit (PICU). Katz, Kelly and His
examined the occurrence of opioid withdrawal in critically ill children who had received
continuous infusion fentanyl for greater than twenty-four hours.5 Using the Neonatal
Abstinence Scoring Scale (NAS) on a population (n=23) of children ranging in age from
one week to twenty-two months, they found a high incidence of opioid withdrawal that
was both dose and duration dependent. It should be noted that the practitioners used a
very aggressive weaning regimen entailing a dose reduction of fifty percent each day for
two days and then discontinuation of the opioid on day three. Subsequent research has
found that this type of rapid taper, which was the norm at the time, invariably results in
withdrawal. A few years later, Carnevale and Ducharme conducted an observational
study to examine adverse reactions to opioid and benzodiazepine withdrawal in critically
ill children.6 Although their study was limited by the small sample size (n=5) and the lack
of a validated assessment tool, the resulting observations of relationships between
types of behavioral symptoms across a variety of clinical contexts did contribute to the
generalizability of opioid withdrawal symptoms over multiple patient populations. In
2005, the same authors used a prospective multiple case study design to observe the
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effects of variable weaning rates on incidence of opioid and benzodiazepine withdrawal
symptoms.7 The pediatric intensive care unit patients (n=27) ranged in age from one
month to nineteen years. Again, the authors used a relatively small sample size and did
not use a validated assessment tool and instead relied on data collection gleaned from
nurses’ notes. Despite these limitations, the authors did note the need to tailor the
percentage of wean to the length of time on opioids. Pederson and Parran used a daily
patient self-report log on a post hematopoietic cell transplant cohort of patients ranging
in age from seven to sixty-four years and found that the length of taper needed to avoid
withdrawal symptoms correlated with both pretaper opioid dosage and length of
pretaper opioid therapy.8 Furthermore, withdrawal symptoms were highest on taper
days two through six. In a prospective repeated measures design study using the
Sophia Benzodiazepine and Opioid Withdrawal Checklist (SBOWC), Ista and
colleagues found that the most common symptoms of opioid withdrawal in children
ranging in age from zero days to sixteen years (n=79) included sleeplessness,
increased temperature, diarrhea, tremors and pupil dilation.9 Only one randomized
double blinded trial was found.10 PICU patients (n= 37) with an average age of nine
years were randomized to a five or ten day weaning protocol with both groups receiving
enteral methadone. The authors found no significant difference between the five day
and ten day wean groups. Limitations of this study include the small sample size and
the use of an assessment tool (NAS) only validated for assessment of neonatal
abstinence.
Opioid withdrawal review articles. Due to the paucity of articles related to
pediatric opioid withdrawal, two review articles were included. Ista and colleagues

9

published a literature review with similar recommendations to employ strategies to
decrease the amount of opioid administered.11 Since the majority of studies conducted
on children used assessment tools validated in a neonatal population they may have
produced unreliable results. The authors conclude that an appropriate assessment tool
for use in the pediatric population is sorely needed. During the same year, Bartolome
and colleagues published a literature review with the intent of gleaning analgesia and
sedation management recommendations from the existing body of evidence. 12 As with
the Ista group, the authors found many gaps in the existing literature including the
existence of an appropriate assessment tool to facilitate avoidance of adverse effects
such as opioid withdrawal.
Opioid withdrawal assessment tools for children. Only two studies attempted to
develop an opioid withdrawal tool for children. 13, 14 Both tools were developed by the
same team of researchers. In fact, the latter tool is merely a revision of the first tool. The
Opioid Benzodiazepine Withdrawal Scale (OBWS), a 21 item assessment instrument,
was tested in PICU patients who were undergoing opioid and benzodiazepine tapering.
Out of fifteen patients, thirteen experienced symptoms of withdrawal despite the use of
a tapering protocol and the OBWS. The most common symptoms witnessed were
sleeplessness, tremors, mydriasis and diarrhea and occurred as late as six days after a
greater than ten percent taper in opioid. Initial psychometrics were adequate, but could
be improved (sensitivity= 0.50; specificity=0.87). A subsequent multicenter prospective
repeated measures study assessing the predictive validity of a newly revised nineteen
item scale ensued. The resulting Withdrawal Assessment Tool-1 (WAT-1) effectively
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replaces the first tool with its far superior psychometric performance (sensitivity= 0.872;
specificity=0.88).14
One study developed an opioid and benzodiazepine withdrawal scale for
children. The Sophia Observation Withdrawal Symptoms scale (SOS) is a 15 item scale
that takes into account the overlap of opioid and benzodiazepine symptoms of
withdrawal.15 In comparison to the WAT-1 (7 minutes), the SOS takes a mere 2
minutes to complete.
Algorithms or protocols for opioid weaning. Within all of the included articles, the
authors allude to varying opioid tapering practices (Table 2). Only one study used an
assessment based tapering algorithm. Parran and Pederson conducted a quasiexperimental study that tested the impact of use of an opioid tapering algorithm on the
incidence of opioid withdrawal symptoms.16 Their study included 106 patients who were
one month post hematopoietic cell transplant. The ages of participants ranged from 5 to
64 years. The authors concluded that the total reports of withdrawal symptoms
positively correlated with length of taper (r=0.46, p<0.001). That is, with a longer taper,
there were fewer symptoms of withdrawal. Overall, the results indicated a decrease in
incidence of opioid withdrawal symptoms for those patients who were tapered with use
of the opioid taper algorithm.
Conclusions
Implications for Practice. This review supports the need for a pediatric opioid
withdrawal assessment tool with excellent psychometric properties that can be used in a
variety of settings. The WAT-1 instrument certainly appears promising. Since the
majority of PICUs routinely use a combination of benzodiazepines and opioids for
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sedation and analgesia, the recently published development of the SOS scale, with its
short application time and attention to both opioid and benzodiazepine withdrawal
symptoms, merits a deserved second glance. Several studies demonstrated the need
for adherence to a dose and duration dependent tapering protocol with ongoing
assessment and reassessment for withdrawal symptoms.
Multiple opportunities abound for the advanced practice nurse to positively
influence practice and outcomes. In order to avoid immediate and potentially long term
harm, the advanced practice nurse can lead the development of evidence based
practice guidelines for opioid tapering in the pediatric population. By using the
information drawn from a validated opioid withdrawal assessment tool to guide practice,
the advance practice nurse has the ability to individualize the opioid tapering plan for
each child. Besides the obvious ethical implications of prevention and treatment of
suffering, the advanced practice nurse has the ability to contribute to the overall care of
the patient by providing optimal symptom management and efficient, assessment based
opioid tapering. As we enter into an era of ever increasing restrictions on the provision
of and reimbursement for health care, the advanced practice nurse is in an ideal
position to guide care with a goal of prevention of unnecessarily lengthy
hospitalizations. Overall, the efficacy of an assessment-based opioid tapering regimen
may result in improved patient outcomes, greater provider satisfaction and confidence,
enhanced family satisfaction and potential cost savings.
Implications for Research. With the advent of validated, pediatric-specific, opioid
withdrawal instruments, opportunities abound for future research. Further research is
needed to test the WAT-1 and SOS tools in settings outside of the PICU. Replicative
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studies are now possible substituting an appropriate assessment instrument for the
pediatric population such as the WAT-1 or the SOS for the NAS. Although the focus of
the majority of the studies was the incidence of withdrawal symptoms experienced by
the children, the tapering protocol used for and during the studies provides guidance for
the future development of an evidence-based tapering algorithm. Additional studies of
importance include evaluation of improved outcomes such as decreased length of stay,
decreased length of taper, and avoidance of unnecessary diagnostic testing secondary
to enhanced capability to accurately assess and diagnose withdrawal.
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Table 1. Studies Included in Critical Review
Year Authors
Sample
Design
(age)
1994 Anand & Arnold NA
Literature Review
1994 Katz, Kelly &
23
Prospective, case
His
(1 wk-22m) series
1997 Carnevale &
5
Prospective,
Ducharme
(2m-16m)
multiple case study

2000

Pederson &
Parran

45
(7-64 yrs)

Prospective,
descriptive

2002

Parran &
Pederson

106
(5-64 yrs)

Quasi-experimental

2004

Franck et al.

Prospective,
repeated measures

2005

Berens, et al.

15
(6wks –
28m)
37
(36 wks –
18yr)

2005

Ducharme et al.

27
(1m- 19 yr)

Prospective,
randomized double
blind methadone
wean
Prospective,
multiple case study

2007

NA

Literature review

2007

Bertolome, Cid
& Freddi
Ista et al.

NA

Literature review

2008

Franck et al.

83

2008

Ista et al.

79
(0-16 yrs)

Multi-centered
prospective
psychometric
evaluation
Prospective,
repeated measures

2009

Ista et al.

Key Findings
NAS preferred
 withdrawal seen in >5 days
duration of therapy
inconsolable crying, tremors,
jitteriness, irritability, gagging,
vomiting & feeding problems
< 24 hr post wean
Withdrawal symptoms highest on
taper days 2 through 6
Length of taper correlated with both
pretaper opioid dosage & length of
pretaper opioid therapy.
Positive relationship between
length of taper & total reports of
withdrawal symptoms (r= 0.46,
p<0.001)
OBWS developed
Sensitivity = 0.50
Specificity = 0.87
No difference in withdrawal
between 5 day or 10 day
methadone wean
Final weaning recommendations:
1-3 day= 20% wean per day
4-5d= <20% wean per day
6-7d= 13% wean per day
8-14d= 8-13% wean per day
15-21d= <8% wean per day
>21d= 3% wean per day
Lack of individualized tapering
regimens
Overlap of withdrawal symptoms
for opioids & benzodiazepines
OBWS revised to create WAT-1
WAT-1 validated
Sensitivity = 0.87
Specificity = 0.88
Most frequent symptoms=
Sleeplessness, temp, diarrhea,
tremors & pupil dilation
SOS developed

79
Instrument
(0-16 yrs)
validation
d=day; m= month; NA= non-applicable; NAS= Neonatal Abstinence Score; OBWS= Opioid
Benzodiazepine Withdrawal Scale; SOS= Sophia Observation withdrawal Symptoms scale;
wk=week; WAT-1= Withdrawal Assessment Tool; = increased
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Table 2. Summary Tapering Techniques During Opioid Weaning
Year Authors N
Age
Opioid (O) Assessment Tapering
or
Tool
Technique
Benzo (B)
1994

Katz, Kelly
& His
Carnevale
&
Ducharme
Parran &
Pederson

23

2004

2005

1997

2002

<2
years
2m 16m

Fentanyl

NAS

O&B

No tool sited

106

5-64
years

O

Franck et
al.

15

6wk –
28m

O&B

Ducharme

27

0 – 19
yrs

O & / or B

0-10 or
FACES
14 symptom
withdrawal log
Interview
Medication
Profile
OBWS
Nurses’ clinical
judgement
Medical record
review
Nurses’ notes

5

Incidence
of
Withdrawal
Symptoms

Fentanyl weaned
50% every 24h
>25% to 50% within
24 hours

57%

Algorithm

16%

>14 days = 10%
daily 
> 5 days = 20%
daily 

87%

100%

Duration of
NA
exposure
(recommended
daily wean)
a) 1-3 days (20%)
b) 4-7 days (1320%)
c) 8-14 days (813%)
d) 15-21 days
(<8%)
e) > 21 days (3%)
2008
Ista et al.
79
0-16
O&B
SBOWC
34%
 morphine by 10
yrs
g/kg/hr every 24h;
 midazolam
50g/kg/hr per 8
hrs
Benzo = benzodiazepine; hr = hour; hrs= hours; kg= kilogram; g = microgram; m= month; N=
sample size; OBWS = Opioid Benzodiazepine Withdrawal Scale; SBOWC= Sophia
Benzodiazepine and Opioid Withdrawal Checklist; NAS= Neonatal Abstinence Scoring System ;
wk= week; yrs=years; ↓= decrease

18

CHAPTER 3. OPIOID WITHDRAWAL SIGNS AND SYMPTOMS IN CHILDREN:
FREQUENCY AND DETERMINANTS

INTRODUCTION
Over 90% of critically ill children receive opioids.2 Routine use of analgesia and
sedation for critically ill, ventilated children is essential for the child’s comfort and safety
and to protect the child from self-harm due to unplanned endotracheal extubation,
anxiety related increased oxygen demand and ventilator dysynchrony. 8 However the
therapeutic goal of providing adequate analgesia and sedation often results in days to
weeks of continuous exposure to opioids and sedatives. Continuous exposure may
result in iatrogenic opioid and sedative dependence. Opioid dependence is defined as a
state of adaptation that is manifested by a drug class specific withdrawal syndrome that
can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of
the drug, and/or administration of an antagonist.4 Opioid tolerance is defined as a state
of adaptation in which exposure to a drug induces changes that result in a diminution of
one or more of the drug's effects over time.4 Once the child no longer needs the opioid
or sedative, the medications are reduced over time. The goal of tapering is to safely
wean the opioid dose while avoiding opioid withdrawal. Opioid withdrawal refers to signs
and symptoms that occur following an abrupt discontinuation or rapid decrease in an
opioid after opioid dependence has developed. Unfortunately, there is little empirical
evidence to guide the practice of opioid tapering.3,9,10 Since opioid tapering practices
vary among practitioners, it is not uncommon for nurses to witness signs and symptoms
of withdrawal in this vulnerable population. Opioid withdrawal signs and symptoms in
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children include diarrhea, nausea, vomiting, fever, sweating, mottling, tremor, agitation,
frequent yawning, frequent sneezing, motor disturbance, insomnia and hypertonia. 1,3,7,919

Few data have been published on the incidence of opioid withdrawal in the
pediatric population with the reported incidence of opioid withdrawal varying widely (0100%).1,9,11,20 In addition, studies of opioid withdrawal conducted in the pediatric
population have used neonatal withdrawal tools1,9,11,20-22 or no opioid assessment tool.912

The use of developmentally inappropriate tools such as neonatal opioid withdrawal

tools may result in conclusions that are flawed. In 2008, Franck et al. developed the
Withdrawal Assessment Tool-1 (WAT-1) (Fig 1), a pediatric opioid withdrawal scale.3,10
Presently, the WAT-1 is the only validated pediatric opioid withdrawal assessment tool.
Although another tool, the Sophia Observation withdrawal Symptoms scale (SOS), has
also been developed, its psychometric properties have yet to be published. 13 Except for
the initial and subsequent tool validation studies of the WAT-1, no studies have been
conducted to identify the incidence of pediatric opioid withdrawal using a validated
pediatric opioid withdrawal assessment tool.7,23 In addition there are few data about
factors that may affect the frequency of withdrawal signs and symptoms including opioid
exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure),
opioid taper rate, and the child’s age.1,3,7,9-14,16-21,24 Further, PICU length of stay (LOS)7,
duration of mechanical ventilation (LOMV) and cumulative opioid dosage (mg/kg) are
positively associated with signs and symptoms of opioid withdrawal.7,19,20 Although
associations among opioid duration9,17,20,21 and cumulative dose20,21 prior to taper and
occurrence of opioid withdrawal signs and symptoms have been identified, data
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concerning other factors (peak opioid dose9, opioid taper rate and age7) that may affect
opioid withdrawal signs and symptoms are limited.
Although pediatric guidelines for opioid tapering exist, they are based on little
empiric evidence.1,9,25,18,25 In order to describe present opioid tapering practices by
pediatric practitioners, we conducted a cross-sectional web based survey14 using
international pediatric pain and palliative care email list serves. Of the 104 respondents,
only 22 (27%) had a written protocol for opioid tapering. Respondents without a protocol
reported regimens for opioid withdrawal that varied greatly. In addition, only half of the
respondents (n=52) used an opioid withdrawal assessment tool. Of those using an
assessment tool, the majority used the WAT-1 (n=22) followed by the Finnegan
Neonatal Abstinence Score (NAS) (n=14).14
This study will investigate the incidence of opioid withdrawal and factors
associated with development of opioid withdrawal in a pediatric population. More
importantly, our study will measure opioid withdrawal using a validated, pediatric tool –
the WAT-1. Accurate assessment of opioid withdrawal is important for several reasons.
The acute effects of withdrawal not only result in discomfort but can be dangerous as
well. Diarrhea and vomiting can lead to dehydration and tachycardia may lead to
unnecessary intravenous fluid resuscitation or cardiology evaluations. Poorly managed
signs and symptoms of opioid withdrawal may lead to prolonged LOS.
Therefore, the purpose of this study is to describe the frequency of opioid withdrawal
signs and symptoms and to identify factors associated with these opioid withdrawal
signs and symptoms. The specific aims of this study are to (1) describe the signs and
symptoms (WAT-1) of opioid withdrawal in children undergoing opioid tapering and (2)
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examine the relationship among opioid withdrawal signs and symptoms (WAT-1), opioid
exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure),
opioid taper rate, and the child’s age.
METHODS
Setting and Sample
The study was conducted in the Pediatric Intensive Care Unit (PICU), the
Pediatric Progressive Care Unit (PPCU) and the acute care pediatric units at the
Children’s Hospital of Richmond, Virginia Commonwealth University Health Systems
(VCUHS). The PICU, the PPCU and acute care areas, admit children with a wide range
of pediatric diagnoses enhancing generalizability of study findings.
The sample of 26 were drawn from all patients, ages 2 weeks to 21 years,
admitted to the PICU who had received continuous or scheduled infusion opioids for
greater than 5 days.1,7,17,20 Previous studies have found that opioid tolerance may occur
after 5 days of opioid exposure18,20,26 and that opioid withdrawal signs and symptoms
are highest during taper days 1 through 6. Therefore children were enrolled in the study
and data collection occurred daily up to 7 days.3,11,12,21,27 Pediatric patients (2 weeks to
21 years) from all ethnic and racial backgrounds were recruited. Since restlessness is
part of the WAT-1 evaluation, children with paralysis of one or more limbs or who were
receiving neuroparalytics were excluded.
Measurement of Key Variables
Opioid Withdrawal Signs and Symptoms. Opioid withdrawal signs and symptoms
were measured using the 11 item Withdrawal Assessment Tool – 1(WAT-1) (Fig 1). The
WAT-1 is a pediatric opioid withdrawal tool that evaluates three categories of symptoms
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with symptom scores ranging from either 0-1 or 0-2 based on the type of symptom and
its severity. It includes measures of gastrointestinal symptoms (diarrhea, nausea,
vomiting), autonomic (fever, sweating) and central nervous system (tremor, sedation
state, uncoordinated movement, yawning or sneezing, startle to touch, muscle tone and
time to gain calm) signs and symptoms of opioid withdrawal.7 The 19 item WAT-1 was
tested in a pediatric critical care population (n=83; 1040 observations) ranging in age
from 6 months to 10 years. Redundant signs and symptoms and symptoms with low
levels of association with withdrawal intensity ratings were eliminated resulting in the
current recommended 11 item (12 point) tool. The original validity and reliability testing
revealed high sensitivity (0.87) and specificity (0.88). Further psychometric evaluation of
the tool was conducted in a multicenter prospective repeated measures design study
which included pediatric critical care and general care patients (n=126; 836
observations).23 The WAT-1 has four steps. First, the previous 12 hours are reviewed
for stooling, vomiting and fever. Second, the subject is observed for 2 minutes prior to
any stimulus for behavior state, tremor, sweating, uncoordinated movement, yawning
and sneezing. Third, a 1-minute progressive stimulus is used to assess startle to touch
and muscle tone and fourth, a post stimulus observation is used to assess time to gain
calm. Total WAT-1 scores range from 0-12 and a score of 3 or greater indicates
presence of opioid withdrawal.7
Opioid Exposure. Withdrawal signs and symptoms may be affected by both the
opioid cumulative and peak dose administered during opioid therapy. Therefore opioid
exposure will include these variables as well as opioid duration. Previous studies have
shown that the duration of opioid receptor occupancy is related to the development of
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opioid tolerance.3,22,28,29 In a prospective study conducted by Katz et al. (1994), 23
infants (<23 months) were observed for signs of opioid withdrawal post opioid exposure
using the Neonatal Abstinence Scale, an tool designed for the neonatal population. 20
They found a positive correlation of dosage (p<0.005) and length of exposure
(p<0.0001) with opioid withdrawal symptoms. In fact, a cumulative dose of 2.5mg/kg
fentanyl or more than 9 days exposure was 100% predictive of withdrawal. Although the
results of these studies are compelling, study limitations, including small sample size,
narrow age range and use of a developmentally inappropriate tool may affect
generalization to the pediatric population. Further, the relationship between peak opioid
dose and opioid withdrawal is limited to one study.9 In a prospective study of critically ill
children (n=27), Ducharme et al.9 found a significant relationship (r=0.34; p<0.05)
between peak opioid dose and opioid withdrawal. However, opioid withdrawal was
measured indirectly by reviewing nurses’ documentation.
Opioid Dose. Several previous studies have found a relationship between
cumulative opioid dose and opioid withdrawal although most have been either
conducted in infants only or in pediatrics using a measurement tool designed for infants.
In one of the first studies to investigate the relationship between potential risk factors
(opioid exposure and withdrawal) using a prospective study of infants ranging in age
from 1 week to 22 months, Katz et al. found that a total dose of 1.5mg/kg was
associated with a 50% rate of opioid withdrawal.20 Other studies conducted in children
have found a similar dose dependent relationship.9,21,26 In a prospective, multiple case
study (n=27), Ducharme and colleagues examined the effects of variable opioid taper
rates on occurrence of opioid withdrawal on PICU patients (age 0-19 years). They found

28

a small but significant association between opioid peak dose and occurrence of
withdrawal (r=0.34; p<0.05).9 One opioid specific study examined the relationship
between fentanyl, the preferred opioid in pediatric critical care, and opioid withdrawal. In
this prospective, descriptive opioid withdrawal study of critically ill infants and young
children (< 25 months), French and Nocera found a strong correlation between
cumulative fentanyl dose and opioid withdrawal score (r=0.76; p<0.01).21 Likewise, in a
retrospective study of neonates, Arnold and colleagues found a total dose of 1.6mg/kg
to be associated with the development of opioid withdrawal.26 However all of the results
described here are limited by narrow age range of the study populations, small sample
sizes and the use of opioid withdrawal assessment tools designed for neonates in an
older population. Because the literature shows a relationship between cumulative and
peak opioid dose on occurrence of opioid withdrawal opioid withdrawal, opioid dose was
described as both cumulative and peak.9,20,21,26
To compare analgesics across types, all opioids were converted to morphine and
reported as morphine equivalents per kilogram (MEK).12,17 For this study, fentanyl
conversion to morphine was calculated by the formula 10mg of IV morphine = 0.1mg IV
fentanyl.30 Daily dose of MEK was calculated. Peak and cumulative MEK were
calculated pretaper and daily during taper. The largest daily MEK was recorded as the
peak opioid dose. Cumulative dose was determined by summation of daily MEKs prior
to initiation of opioid taper.
Opioid Duration. Previous studies have found that duration of opioid exposure
effects opioid withdrawal. Ducharme and colleagues found a moderate association
between opioid duration and occurrence of opioid withdrawal (r=0.41; p<0.01).9 Katz et
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al. found that a duration of 5 days or more of fentanyl exposure was 50% predictive of
opioid withdrawal.20 French and Nocera found a significant correlation between duration
of fentanyl exposure and opioid withdrawal score (r=0.70; p<0.05).21 In a prospective,
repeated measures design study of critically ill children (n=79; ages 0 to 16 years), Ista
and colleagues found a significant correlation between duration of opioid exposure and
severity of opioid withdrawal (r=0.52; p<0.001).17 In this study opioid duration was
calculated as the number of days of continuous or scheduled opioid exposure prior to
initiating opioid taper. Only children with at least 5 days of opioid exposure were eligible
for the study.
Opioid Taper Rate. Although opioid tapering recommendations exist in the
literature, few are based on empiric evidence.1,9,18,25,31 Since rates of taper vary
depending on clinician, opioid tapering rate was defined as dose change per day,
expressed in morphine equivalent units per kilogram (MEK) of the child’s body weight.
Nonscheduled opioids that were administered were included in the daily opioid tapering
rate calculation. The MEK/day was compared to the previous day’s MEK/day dose. In
addition, medications that may alleviate withdrawal signs and symptoms such as
benzodiazepines, -adrenergic (clonidine, dexmedetomedine), antiemetics and
antipyretics were recorded.
Procedures
Prior to beginning the study, an informational in-service was provided to the
pediatric nursing leadership and staff of the involved units. The study was approved by
the VCU Institutional Review Board at VCU and included waiver of assent since the
pediatric participants were sedated during the observation period. Permission was
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obtained from the parent/legal guardian at time of study enrollment. Patients who met
selection criteria were identified through daily PICU rounds. Data obtained did not affect
the participant’s routine care nor was it used in the clinical management of opioid
tapering.
Data collection timing occurred daily, for up to 7 days, between 10 AM and 4 PM
during times of routine care in order to allow a consistent time point from the previous
day’s opioid dosing changes and avoid the usually busy early morning clinical rounds.
The exact time was negotiated with the bedside nurse in order to minimize any potential
disruption of routine care. At the time of study enrollment, the following data from the
electronic medical record (EMR) and bedside flow sheet were collected: medications
received within the past 24 hours, data to calculate opioid cumulative dose (in MEK)
peak opioid dose (in MEK), and number of days of opioid exposure prior to study
enrollment demographic data (age, race, gender, admission diagnosis, weight in
kilograms).
Data collection for the opioid taper rate occurred each day for up to 7 days. We
collected opioid dose information given over the past 24 hours (8a to 8a). All opioids
were converted to MEK. The sum of the MEKs was recorded as the MEK/day.
Data collection for the WAT-1(Fig1) began with a review of the EMR and flow
sheet for the previous 12 hours followed by direct observation for 2 minutes and then a
1 minute progressive stimulus observation. During the direct observation data was
collected on state, tremor, sweating, uncoordinated/repetitive movements and yawning
or sneezing. Next, the patient was observed during the1 minute progressive stimulus.
During the 1 minute progressive stimulus observation, data on muscle tone and startle
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to touch was collected. Finally, the patient was observed for up to 5 minutes to assess
time to recovery post stimulus. The WAT-1 was measured daily for up to 7 days. With
the exception of 4 observations, all WAT-1 measurements were collected by the same
investigator. Training for the second evaluator consisted of didactic review of the tool
and its use followed by simultaneous WAT-1 assessments with the primary investigator.
Once agreement was met on how to use the WAT-1, the second investigator was
allowed to obtain data independently using the WAT-1.
Data Analysis
Demographic variables were summarized and measures of central tendency
(mean, median) and dispersion (standard deviation, range) were calculated on
continuous data, and frequency and counts were computed on categorical data.
Descriptive statistics (means and standard deviations) were used to address the
first study aim. Individual variable scores and total WAT-1 scores were recorded. For
the second aim distributions of all study variables were examined to determine the need
for transformations. The opioid duration and cumulative opioid dose data were skewed
therefore log transformations were done to stabilize the variance and make the
distributions more normal. These transformed values were used in all analyses.
Correlational analyses were used to examine the relationship among opioid withdrawal
signs and symptoms (WAT-1), and opioid tapering rate, opioid exposure (log cumulative
opioid dose, peak opioid dose, log duration of opioid exposure), and the child’s age.
Plots were produced to describe the change in individual symptoms over time and the
relationship between average opioid dose and average total WAT-1 score over time.
Mixed effect repeated models were used to determine if the changes in the WAT-1
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score over study days 1 to 7 were due to 1) log opioid duration, 2) log cumulative opioid
dose, 3) age, 4) gender, 5) race, 6) LOMV and 7) ICU LOS. For every comparison
performed in this study, the significance level was set at p<0.05.
RESULTS
Participants
Twenty-eight patients met inclusion criteria. Since two families declined
participation, twenty-six (93% of those eligible) were enrolled in the study. One
participant who was on Extracorporeal Membrane Oxygenation (ECMO) was excluded
at analysis due to his extreme cumulative opioid dose (10 fold increase over next
largest value) and potentially confounding severity of illness. Thus the twenty-five
participants had a mean age of 6.7 years (79.8 months) and were primarily male and
white (Table 1). The majority (n=21) were enrolled from the Pediatric Intensive Care
Unit and respiratory illness, trauma and post-operative management were the most
common admission diagnoses. Most (n=19) were ventilated and the median duration of
mechanical ventilation for those ventilated was 8.5 days (IQR=5 – 18.5 days) (Table 1).
Median length of opioid duration was 8 days (IQR=5 – 15.5 days) (Table 3). Opioid
taper rates varied widely from an average daily dose reduction of 24.4 MEK between
observation days 1 and 2 to an increase of 14.05 MEK between days 1 and 2 (Table 4).
Signs and symptoms of opioid withdrawal
A total of 155 WAT-1 observations were performed in 25 participants over the 7
day study period. Of the 25 participants, 18 had observations for all 7 days. No
participant had a daily WAT-1 total score greater than 7 (possible score 0-12). For the
25 participants 11(44%) had a WAT-1 score of greater than or equal to 3 on any given
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day, indicating presence of opioid withdrawal. Of these 11, 6 (55%) were White and
were males (56%). Only one participant had a rating greater than 5 (WAT-1 score =7),
and 54% did not have opioid withdrawal (WAT-1 score < 3).
The most common symptoms noted over all days were diarrhea (35%), sweating
(25%) fever (21%), and vomiting (20%) (Table 2). Peak occurrence of symptoms, that
is, highest WAT-1 score, was noted on day 2 (mean=2). The days with the least
occurrence of symptoms were day 6 and day 7 (Table 2).
Opioid Withdrawal, Exposure and Tapering
The second study aim included an examination of the relationship between signs
of opioid withdrawal and opioid exposure (opioid duration, cumulative opioid dose, peak
opioid dose). Participant median duration of opioid exposure was 8 days and ranged
from 5 to 15.5 days (Table 3). Eight (73%) participants with opioid withdrawal had
longer than 9 days duration of opioid treatment prior to tapering. There was a positive
relationship between log opioid duration and the maximum WAT-1 score that
approached significance (r=0.38, p=0.06). Similarly, there was a positive relationship
approaching significance between opioid duration and the average WAT-1 for days 1
through 7 (r=0.33, p=0.10). The effect of opioid duration on the total WAT-1 was
compared across days 1 to 7 using mixed models repeated measures ANOVA and no
significant differences among the days were found (F(1,24)=2.46; p=0.13). Median
cumulative opioid exposure was 49.12 MEK (IQR= 16.6-124.6) over time. We found that
all (100%) participants with opioid withdrawal (WAT-1 ≥ 3) had cumulative opioid doses
greater than 2.5 MEK. There was no relationship between the cumulative opioid dose
and the maximum WAT-1 (r=0.29, p=0.15), or the average WAT-1 (r=0.22, p=0.28). In
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addition, no significant differences was found between days for average WAT-1
(F(1,25)=1.09; p=0.313). Median peak opioid exposure prior to taper was 9.8 MEK
(IQR=16.6-124.6). Peak opioid dose was not related to the average WAT-1 (r=0.28;
p=0.17) or the maximum WAT-1(r=0.17; p=0.42).
Although in general a steady reduction in opioid dose during the tapering process
is suggested, we found wide variability in opioid dose changes (tapering or increases)
each day. Opioid dose changes included both tapering and increases in 22 (88%)
participants over the study days. The remaining 3(12%) patients had opioid doses that
only decreased each day (Figure 2). In addition, variability in dose was most severe
during the first 2-3 days of the taper process, leveling off during days 4 through 7.
Opioid Withdrawal and Other Factors
Demographic data included gender, race, LOMV, ICU LOS and age. For these
variables, the only effect noted was between age and peak opioid dose (r=-0.41;
p=0.04). The effect of these variables on the total WAT-1 was compared across days 1
to 7 using mixed models repeated measures ANOVA. There was no significant effect of
age (F(1,23)=1.30; p=0.27), gender (F(1,24)= 0.00; p=0.99), race (F(1,24)= 2.66;
p=0.12), ICU LOS(F(1,20)= 0.56; p=0.46) or LOMV (F(1,18)=2.42; p=0.14) on the total
WAT-1 across days 1 to 7.
DISCUSSION
This prospective, descriptive observational study described the occurrence of
signs and symptoms of opioid withdrawal in critically ill children undergoing opioid taper.
In addition, the relationship among opioid withdrawal signs and symptoms, opioid
exposure, opioid taper rate, and the child’s age was examined.
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Signs and Symptoms of Opioid Withdrawal
The most common symptoms (sweating, diarrhea, vomiting, fever) found in our
study were similar to previous studies.3,7,13 Franck3 and Ista17 found in critically ill
children that sleeplessness, fever, diarrhea, tremors and pupil dilation were the most
common. Since our withdrawal tool did not include an evaluation of sleeplessness, or
pupil dilation, comparisons to our study cannot be made.
We found a low incidence of opioid withdrawal with only half of the sample
having opioid withdrawal on any given day. Prior to study implementation, staff
perception of the incidence of opioid withdrawal led us to expect a higher incidence.
Also, our findings are lower than those noted by Frank et al.7 in the original WAT-1
validation study (44% vs. 64%). In addition our findings showed little variability in
severity of symptoms in those who had opioid withdrawal. That is, the level of symptoms
was not high and very few subjects scored greater than 5 on any given day (WAT-1
score ranges 0 to 12). Since tapering regimens often vary among practitioners 14 we
anticipated varied practice with a resulting wider range of withdrawal signs and
symptoms in our study as well.
Although opioid taper rate did not affect withdrawal symptoms, we found a wide
variation in opioid tapering practice among the pediatric critical care providers at our
institution. For example, some practitioners tapered opioid doses by 30-60% per day,
while others used a more conservative approach (5-20% taper per day). Further, opioid
rescue doses were not used in a consistent manner; i.e. prescribed when one or
multiple withdrawal signs or symptoms were present; rather than using a symptom
threshold for treatment initiation. Even though our sample differed from Franck et al.7
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with longer durations of exposure (8 vs. 6 days) and higher peak opioid doses (9.8 MEK
vs. 7.6 MEK), the resulting level of withdrawals symptoms was similar. Differences in
severity of illness and opioid management may account for these findings. Individual
practitioners may vary in their definition of optimal level of sedation and analgesia,
opioid type and use of opioid sparing adjuvant medications. However our participants’
cumulative opioid dose (49.1 MEK vs. 48.2 MEK) was similar to that found by Franck et
al.7
Opioid Exposure
Since withdrawal signs and symptoms may be affected by both opioid dose
(cumulative and peak) as well as duration, we included these in our measure of opioid
exposure. Similar to other studies, peak opioid dose did not affect opioid withdrawal.
Previous studies have found a similar relationship between cumulative dose and opioid
withdrawal. In a prospective study conducted by Katz et al. (1994), 23 infants (<23
months) were observed for signs of opioid withdrawal post opioid exposure. 20 They
found the occurrence of opioid withdrawal increased as cumulative dose (p<0.005)
length of exposure (p<0.0001) increased. Other studies conducted in children have
found a similar dose dependent relationship.9,21,26 In a prospective, multiple case study
(n=27), Ducharme and colleagues found, in PICU patients (age 0-19 years), that as
opioid peak dose increases, occurrence of withdrawal also increases, although the
association was weak (r=0.34; p<0.05).9 The majority of pediatric literature has been
conducted in a neonatal or infant population. In a retrospective study of neonates,
Arnold and colleagues found a cumulative dose of 1.6mg/kg or greater to be associated
with the development of opioid withdrawal.26 Similar to others, our findings suggest that
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as duration of exposure increases, risk of opioid withdrawal increases. However, we did
not find a relationship between cumulative dose and opioid withdrawal. In the existing
literature on opioid withdrawal in children, only our study and Franck’s7,23 have used a
validated pediatric opioid withdrawal instrument.
We found that increases in cumulative dose may also increase the potential for
opioid withdrawal (Figure 2). Several pediatric studies had similar findings. In a
prospective, descriptive opioid withdrawal study of critically ill children (<25 months),
French and Nocera found a significant correlation between cumulative fentanyl dose
(≥5.6 MEK) and opioid withdrawal score (r=0.76; p<0.01).21 Ducharme and colleagues
found a moderate association between opioid duration and occurrence of opioid
withdrawal (r=0.41; p<0.01).9 Katz et al. found that a duration of 5 days or more of
fentanyl exposure was 50% predictive of opioid withdrawal.20 French and Nocera found
a significant correlation between duration of fentanyl exposure and opioid withdrawal
score (r=0.70; p<0.05).21 In a prospective, repeated measures design study of critically
ill children (n=79; ages 0 to 16 years), Ista and colleagues found a significant correlation
between duration of opioid exposure and severity of opioid withdrawal (r=0.52;
p<0.001). Similar to our study, these researchers found a dose dependent relationship
between duration of opioid exposure to opioid withdrawal. Our results in conjunction
with the previous findings, lead to our recommendation of use of an assessment based
tapering regimen for all patients deemed at risk for opioid withdrawal by nature of their
history of duration of opioid exposure (>5days) and cumulative opioid dose (>2.5 MEK).
Opioid taper rate
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There is little empirical evidence to guide the practice of opioid tapering. 1,9,10,20
Although some theoretical recommendations exist in the literature, 18,31 few data based
guidelines have been tested in the pediatric population. Of those that have been tested,
no guideline was associated with a 0% incidence of opioid withdrawal signs and
symptoms. In this study, we found no significant relationship between opioid taper rate
and incidence of opioid withdrawal. Given the non-linear variation in overall pattern of
opioid taper in our patients, we were unable to detect an association between opioid
taper rate and occurrence of opioid withdrawal. Since the majority of subjects were
tapered using methadone, the longer and variable half-life may have confounded the
relationship between opioid taper rate and subsequent increase in WAT-1 score.
Age
Given the inherent physical developmental differences in children, age-related
differences in the incidence of opioid withdrawal may be expected. At this time, few
studies have investigated age-related differences in the development of opioid
withdrawal. The wide age range of our sample is similar to several previous
studies.1,13,17 However none of these studies reported age related differences in the
incidence or presentation of opioid withdrawal. Only Franck et al. has evaluated the
effect of age on opioid withdrawal signs and symptoms in children.7,20 Using a sample of
children 7 months to 10 years of age, Franck7 found a higher incidence of vomiting in
the 0 to 2 years of age group (12.3%) compared to the >6 years age group (3.2%). In
addition, children greater than 6 years of age (6.1%) had lower incidence of yawning
and sneezing than the 2.1 to 6 year group (13.4%). We found no relationship between
age and average WAT-1 score. Since the majority of the previous studies as well as this
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study are limited by small sample sizes, the possibility that age related symptom
differences do exist cannot be ruled out.
Similarly to Katz et al.20, our findings revealed no association between age and
incidence of opioid withdrawal. Although Franck found some age related differences in
the original WAT-1 validation study7, our study did not have similar findings. Our inability
to detect an association may be reflective of our small sample size. Studies with a larger
sample size may more accurately reflect the developmental differences in children as
they physically mature. Except for Ista13,17 and Franck,7,23 previous studies were limited
by small sample sizes.
Conclusions
Knowledge of opioid withdrawal incidence and its related factors provides
valuable information for proactive opioid management. For those patients with a longer
duration of exposure, the clinician should have a heightened awareness of the potential
for opioid withdrawal and hence the need for a tapering regimen. In conjunction with an
appropriate tapering regimen, use of a validated pediatric opioid withdrawal tool is
essential in the effective assessment and management of opioid withdrawal.
Individualized, assessment based tapering regimens may lead to a shorter length of
stay. Future evaluations of taper regimens using opioids with shorter half-lives may
identify associations between taper rate and occurrence of opioid withdrawal.
Inappropriate management of opioid withdrawal has the potential to increase cost due
to use of unnecessary laboratory or radiological diagnostic testing.
Several limitations should be considered when interpreting our findings. The
generalizability of our findings is hampered by the small sample and use of a single site.

40

The heterogeneity of the participants’ medical conditions may have confounded our
results. Evaluation of the effect on opioid withdrawal was limited by the low variability of
total WAT-1 scores, which may be reflective of the unexpected conservative tapering
practices and other medications may have interfered with appearance of opioid
withdrawal. Further, clinicians were often aware that their patient was enrolled in the
study, which may have led to treatment bias. In addition, since the clinicians did not
make their treatment decisions using a validated assessment tool, the possibility of over
diagnosis is real. The change in tapering practices styles on any given day further
contributed to potential confounding variables for this study. Future studies evaluating
the use of an assessment based tapering protocol would be clinically useful. Although
symptoms of opioid and benzodiazepine withdrawal overlap, not all symptoms of
benzodiazepine withdrawal are addressed by the WAT-1 such as insomnia and
seizures.19 Based on our findings and the findings in similar studies, we agree that
opioid tapering regimens should consider risk factors, such as opioid duration. Whether
other factors, such as age, affect withdrawal is not completely clear. However it is clear
that to successfully identify and manage opioid withdrawal symptoms, use of a valid tool
is imperative. Therefore, tolerance to the tapering regimen should be assessed daily
using a validated pediatric assessment tool.
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Table 1. Participant Characteristics (n=25)
Variable
Mean
a
Age (mo.)
79.8
d

LOMV (days)
ICU LOSe (days)

SDb
61.2

Median
8.5
13

Range
7 to 214

IQRc
5 to 18.5

Range
0 to 35

7.5 to 21.5

1 to 38

Count

Percent

16

64%

9

36%

Asian

1

4%

Black

12

48%

White

11

44%

Other

1

4%

1

4%

24

96%

Gender
Male
Female
Race

Ethnicity
Hispanic
Non-Hispanic
Admission Diagnosis
Trauma

4

16%

Respiratory

7

28%

Post-opf

5

20%

Sepsis

3

12%

Other

6

24%

a

mo. = months; bSD = Standard Deviation; c IQR- interquartile range; dLOMV= Length of
Mechanical Ventilation; eICU LOS = Intensive Care Unit Length of Stay; fPost-op= Postoperative
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Table 2. WAT-1 Individual Variable Scores and Total Daily WAT-1 Score (Means and Standard Deviations) a

Loose watery stools

Day 1
(N=25)
Mean (SD)
0. 38 (0.49)

Day 2
(N=25)
Mean (SD)
0.36 (0.49)

Day 3
(N=24)
Mean (SD)
0.33 (0.48)

Day 4
(N=21)
Mean (SD)
0.33 (0.48)

Day 5
(N=21)
Mean (SD)
0.43 (0.51)

Day 6
(N=21)
Mean (SD)
0.29 (0.46)

Day 7
(N=18)
Mean (SD)
0.33 (0.49)

Vomiting/retching/ gagging
Temperature >37.8oC
State

0.2 (0.41)
0.24 (0.44)
0.16 (0.37)

0.24 (0.44)
0.36 (0.49)
0.08 (0.28)

0.29 (0.46)
0.25 (0.44)
0.13 (0.34)

0.29 (0.46)
0.19 (0.4)
0.14 (0.36)

0.1 (0.3)
0.24 (0.44)
0.14 (0.36)

0.05 (0.22)
0.14 (0.36)
0 (0)

0.17 (0.38)
0.17 (0.38)
0.06 (0.24)

Tremor
Sweating
Uncoordinated/
repetitive movement
Yawning or sneezing
Startle to touch
Muscle tone
Time to gain calm state

0.12 (0.33)
0.12 (0.33)
0.08 (0.28)

0.12 (0.33)
0.32 (0.48)
0.12 (0.33)

0.21 (0.42)
0.25 (0.44)
0 (0)

0.05 (0.22)
0.43 (0.51)
0.05 (0.22)

0.05 (0.22)
0.29 (0.46)
0.1 (0.3)

0.05 (0.22)
0.19 (0.4)
0.1 (0.3)

0.06 (0.24)
0.22 (0.43)
0.11 (0.32)

0.08 (0.28)
0.2 (0.41)
0.52 (1.8)
0.08 (0.28)

0.04 (0.2)
0.12 (0.33)
0.12 (0.33)
0.08 (0.28)

0.13 (0.34)
0.08 (0.28)
0.13 (0.34)
0.08 (0.28)

0.05 (0.22)
0.19 (0.4)
0.05 (0.22)
0 (0)

0.05 (0.22)
0.14 (0.36)
0.14 (0.36)
0.05 (0.22)

0.05 (0.22)
0.1 (0.3)
0.1 (0.3)
0.1 (0.44)

0.06 (0.24)
0.06 (0.24)
0.11 (0.32)
0 (0)

1.8 (1.47)

2 (1.68)

1.96 (1.58)

1.7 (1.45)

1.76 (1.64)

1.14 (1.28)

1.28 (1.02)

Symptoms

Total WAT-1 score
Mean (SD)
a

WAT-1 = Withdrawal Assessment Tool-1. All items scored 0-1 except for time to gain calm - 0-2 points. Total WAT-1 score is the
sum of all items (0-12).
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Table 3. Opioid Exposure
Variable
Opioid Duration (days)
Cumulative Opioid Dose (MEK)b
Peak Opioid Dose (MEK)

Median
8.0
49.1
9.8

a

IQR= Interquartile Range
MEK= Morphine Equivalents per Kilogram

b
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IQRa
5.0 – 15.5
16.6 – 124.6
3.0 – 16.8

Range
5.0 – 22.0
3.8 – 364.3
0.7 – 34.6

Table 4. Opioid Taper (n=25)
Opioid Change
Na
Median (MEK)b
Day 1 to 2
25
-0.5
Day 2 to 3
24
-0.24
Day 3 to 4
24
-0.07
Day 4 to 5
24
0.0
Day 5 to 6
22
0.0
Day 6 to 7
22
-0.23
a

N= Sample Size
MEK= Morphine Equivalents per Kilogram
c
IQR= Interquartile Range
b
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IQRc (MEK)
-3.20 – -0.05
-0.73 – 0.07
-0.64 – 0.15
-0.34 – 0.54
-0.73 – 0.06
-0.94 – 0.0

Range (MEK)
-24.4 – 14.1
-16.2 – 1.6
-2.6 – 1.1
-3.6 – 2.5
-3.8 – 2.9
-3.7 – 2.0

Table 5. Multivariate Correlations (n=25)
Age
log
(months)
Opioid
Duration
Age
(months)
log Opioid
Duration
Peak Opioid
Dose (MEK)
log
Cumulative
Opioid Dose
Mean Opioid
Taper Rate
Mean WAT-1
Day 1 to 7
Max(WAT-1)

1.00

-0.13
1.00

Peak Opioid
log
Mean Opioid
Mean
Dose
Cumulative Taper Rate
WAT-1b
(MEK)a
Opioid Dose
Day 1 to 7
(MEK)
-0.41*
-0.40*
0.14
-0.22

Max
(WAT-1)

-0.06

0.64***

0.67***

0.23

0.33

0.38

1.00

0.83***

-0.21

0.28

0.17

1.00

-0.06

0.22

0.29

1.00

0.05

0.21

1.00

0.83***
1.00

a

MEK = Morphine Equivalents per Kilogram
WAT-1 = Withdrawal Assessment Tool
*p < 0.05
**p < 0.01
***p < 0.001
b
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Figure 1. WAT-1 (need to add post converting document to pdf)
Copyright permission obtained from Franck
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10
mean opioid dose (± std err)
mean WAT-1 score (± std err)

Mean Opioid Dose
Mean WAT-1 Score
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Figure 2. Mean Opioid Dose and WAT-1 Score over Time (n=25)
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Heading and indicate “N/A.”
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Opioid withdrawal signs and symptoms in the pediatric patient during opioid tapering
II. STAFFING
A. In the table below (add additional rows as needed), indicate: (1) key project personnel including the principal
investigator and individuals from other institutions, (2) their qualifications, and (3) a brief description of their
responsibilities.
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the American Association of CriticalCare Nurses
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Consultant
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B. Describe the process that you will use to ensure that all persons assisting with the research are adequately
informed about the protocol and their research-related duties and functions.
Deborah Fisher MS, RN, PNP

•

Prior to beginning the study, all team members will meet to establish agreement on process, duties and function.
Recruitment, enrollment, data collection, data management and analysis, final report and dissemination of findings will be
performed by Ms. Fisher. Dr. Ameringer and Dr. Younger will provide pediatric nursing consultation, pediatric pain
consultation as well as consultation on statistical analysis and quantitative methods. Dr. Elswick will provide expert
consultation for the statistical analysis portion of the study. All team members will be appraised through monthly reports
via email during data collection. All team members will meet prior to data analysis and prior to final report.
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III. CONFLICT OF INTEREST
Describe how the principal investigator and sub/co-investigators might benefit from the subject’s participation in this
project or completion of the project in general. Do not describe (1) academic recognition such as publications or (2)
grant or contract based support of VCU salary commensurate with the professional effort required for the conduct of
the project
Dr. Grap – no conflicts to declare
Dr. Ameringer- no conflicts to declare
Dr.Younger – no conflicts to declare
Dr. Elswick – no conflicts to declare
D. Fisher – no conflicts to declare
IV. RESOURCES
Briefly describe the resources committed to this project including: (1) time available to conduct and complete the
research, (2) facilities where you will conduct the research, (3 availability of medical or psychological resources that
participants might require as a consequence of the research (if applicable), and (4) financial support.
1. Ms. Fisher will devote 6 hours per week towards conduct of this study; data collection is anticipated to take
approximately 4 - 6 months.
2. Study setting is VCU Medical Center, Main 7 PICU and acute care pediatric units
3. No anticipated need for psychological resources; all participants will be under the care of a medical team
4. There is no financial support for this study
V. HYPOTHESIS
Briefly state the problem, background, importance of the research, and goals of the proposed project.
Routine use of sedation and analgesia for ventilated children in the intensive care unit is essential for the comfort
and safety of the child to protect the child from self-harm such as unplanned endotracheal extubation, anxiety related
increased oxygen demand and ventilator dysynchrony.1 However the therapeutic goal of providing adequate analgesia and
sedation often results in days to weeks of continuous exposure to opioids and sedatives. Continuous exposure may result in
iatrogenic opioid and sedative dependence. Few data have been published on the incidence of opioid withdrawal in the
pediatric patient. The studies that have been published vary widely on incidence of opioid withdrawal (0-100%).2-5 Studies
of opioid withdrawal conducted in the pediatric population have used neonatal withdrawal tools2-7 or no opioid assessment
tool was used.3,4,8,9 The use of developmentally inappropriate instruments such as neonatal opioid withdrawal instruments
may result in conclusions that are flawed. In 2008, Franck et al. developed the Withdrawal Assessment Tool-1 (WAT-1), a
pediatric opioid withdrawal scale.9,10 At this time, the WAT-1 is the only validated pediatric opioid withdrawal assessment
tool. In 2009, Ista et al. developed a promising opioid and benzodiazepine withdrawal tool, the Sophia Observation
withdrawal Symptoms scale (SOS), but psychometric properties have yet to be published.11 Except for the initial
instrument validation studies of the WAT-1, no studies have been conducted to identify the incidence of pediatric opioid
withdrawal using a validated pediatric opioid withdrawal assessment tool. In addition there is little data about factors that
may affect the frequency of withdrawal signs and symptoms including opioid exposure (cumulative opioid dose, peak
opioid dose, duration of opioid exposure), opioid taper rate, severity of illness and the child’s age. Therefore, the purpose
of this study is to describe the frequency of opioid withdrawal signs and symptoms and to identify factors associated with
these opioid withdrawal signs and symptoms.
VI. SPECIFIC AIMS
The specific aims of this study are to:
1. describe the signs and symptoms (WAT-1) of opioid withdrawal in children undergoing opioid tapering
2. examine the relationship among opioid withdrawal signs and symptoms (WAT-1), opioid exposure (cumulative opioid
dose, peak opioid dose, duration of opioid exposure), opioid taper rate, severity of illness and the child’s age.

VII. BACKGROUND AND SIGNIFICANCE
Include information regarding pre-clinical and early human studies. Attach appropriate citations.
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Over 90% of critically ill children receive opioids.12 Opioids are used routinely in the pediatric intensive care
population for analgesia, sedation, blunting of physiologic responses to stress, and safety.2,12,13 In addition, the synergistic
effect of opioids in combination with benzodiazepines allows for dose reductions of both opioids and benzodiazepines.14
Continued exposure to opioids can lead to opioid dependence or tolerance. Opioid dependence is defined as a state of
adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid
dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.15 Opioid tolerance is defined as
a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug's
effects over time.15 In children, physical dependence may occur in as little as two to three days of continuous opioid
therapy.16 Opioid dependence has been shown to develop even more rapidly in neonates and infants than in older children
or adults.17 Once the child no longer needs the opioid or sedative, the medications are reduced over time. Since tapering
routines vary among practitioners, it is not uncommon for nurses to witness signs and symptoms of opioid withdrawal in
this vulnerable population.18 Opioid withdrawal signs and symptoms in adults include hiccups, goose bumps, chills, fever,
tachycardia, tachypnea, hypertension, agitation, restlessness, insomnia, nausea, vomiting, diarrhea, cramps, lacrimation,
rinorrhea, yawning, diaphoresis, mydriasis, bone pain, muscle aches and spasms, and seizures.16 Opioid withdrawal signs
and symptoms in children include diarrhea, nausea, vomiting, fever, sweating, mottling, tremor, agitation, frequent
yawning, frequent sneezing, motor disturbance, insomnia and hypertonia.2-6,8-11,13,18-23 Data concerning factors that affect
opioid withdrawal signs and symptoms are limited. Although no studies investigating the effect of gender on withdrawal
signs and symptoms have been conducted in humans, there is evidence of gender differences in opioid tolerance and
incidence of withdrawal in rats. In a study conducted by Craft et al., male rats were found to have a higher withdrawal
score than female rats.24 In addition, there is limited data that show length of stay (LOS) in the PICU, duration of
mechanical ventilation (VLOS) and cumulative opioid dosage (mg/kg) are positively associated with signs and symptoms
of opioid withdrawal. 5,13,23 Acute effects of withdrawal signs and symptoms are numerous and can be dangerous. Diarrhea
and vomiting can lead to dehydration. Tachycardia may lead to unnecessary intravenous fluid resuscitation or even
cardiology evaluations. Routine use of validated opioid withdrawal assessment tools or algorithms is rare.9 18 which may
contribute to delays in diagnosis of opioid withdrawal syndrome and proper treatment. Potential long term effects of
poorly managed withdrawal symptoms are unknown; however, possible consequences include prolonged tapering duration
in response to attempts to alleviate withdrawal signs and symptoms as well as needless physical and emotional suffering.
Of note, only one position statement on opioid withdrawal in children is available in the literature. The American
Academy of Pediatrics (AAP) position statement on neonatal drug withdrawal recommends multimodal maternal screening
for opioid use, enhanced recognition of signs of opioid withdrawal, routine use of appropriate opioid withdrawal tools, and
medication recommendations for opioid or sedative withdrawal.25 However, no such statement exists for the pediatric
population.

VIII. PRELIMINARY PROGRESS/DATA REPORT
If available.
1. Survey of opioid tapering practices of pediatric healthcare providers: A national perspective.18 The purpose of this
study was to describe the current opioid tapering practice of a national sample of health care providers consisting of nurse
practitioners, physician assistants and physicians. Data were collected through a web based survey developed by the
investigator. The 11 item survey was developed through careful review of the literature, evaluated by clinical experts in
pediatric pain management and revised based on their feedback. The survey included multiple choice and open ended
questions that evaluated the following: existence and use of guidelines for opioid tapering, personal preference for opioid
tapering, use of expert consultation for opioid tapering, use of opioid withdrawal assessment tool, and pharmacological
preference for management of signs and symptoms of opioid withdrawal. Content validity and clarity were then
established by a panel of 6 pediatric providers with expertise in advanced practice nursing, medicine and survey methods.
Pilot testing was conducted using 8 pediatric health care providers and further revisions made. The resulting survey was
distributed to pediatric health care providers via international and national pediatric pain and palliative care email list
serves. One hundred and four participants from pediatric pain and palliative care list serves responded to the survey. Of
these, the majority were physicians (62%) followed by pediatric nurse practitioners (16%), clinical nurse specialists (15%),
family nurse practitioners (5%), and doctors of osteopathy (2%). The majority of respondents were employed in an
academic children’s medical center (52%). Median age of years in pediatric practice was 16.33 years. The majority (60%)
did not have a written opioid tapering protocol in their practice setting. Respondents without a protocol described regimens
for opioid withdrawal that varied greatly. Approximately half (n=54) of the 104 respondents used an opioid withdrawal
assessment tool. Of those using an assessment tool, the majority used the WAT-113 (n=22), followed by the Finnegan
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Neonatal Abstinence Score26 (n=14), Clinical Opiate Withdrawal Scale27 (n=6) and the Sophia Observation withdrawal
Symptoms scale11 (n=3). This study provided data illustrating the wide variation in opioid tapering practices among
practitioners.
IX. RESEARCH METHOD AND DESIGN
Include a brief description of the project design including the setting in which the research will be conducted and
procedures. If applicable, include a description of procedures being performed already for diagnostic or treatment
purposes.
The specific aims of this prospective, descriptive study are to 1) describe the signs and symptoms (WAT-1) of
opioid withdrawal in children undergoing opioid tapering and 2) examine the relationship among opioid withdrawal signs
and symptoms (WAT-1), opioid exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure), opioid
taper rate, severity of illness and the child’s age.
Setting
The study will be conducted in the Pediatric Intensive Care Unit (PICU), the Pediatric Progressive Care Unit
(PPCU) and the acute care pediatric units at the Children’s Hospital of Richmond, VCU Medical Center campus in
Richmond, Virginia. The PICU, the PPCU and acute care areas, admit children with a wide range of pediatric diagnoses
providing enhanced generalizability of study findings. Dr. Grap, the student’s primary advisor, is an acute care nurse
practitioner and researcher who has conducted numerous clinical studies in the adult intensive care units as well as one
previous study in the PICU. Ms. Fisher, the student PI, is a pediatric nurse practitioner at the Children’s Hospital of
Richmond and has conducted one prior study in the PICU. Dr. Ameringer is an assistant professor of pediatric nursing at
the VCU School of Nursing. She has conducted several clinical studies in the VCUHS pediatric units.
Table 1. Characteristics of study units from which participants will be enrolled (FY 2009)
Average VLOSb (in days)
Unit / bed #
Annual Admissions
Average LOSa (in days)
PICU/ 12
477
4.0
7.1
PPCU/ 7
348
3.2
NAc
Acute Care Pediatrics
1991
3.9
NAc
M7E/ 17
M7C/ 24
a
= Length of Stay
b
= Ventilator Length of Stay
c
= Not applicable
Sample
The sample of up to 100 will be drawn from all patients, ages 2 weeks to 21 years admitted to the Children’s
Hospital of Richmond Pediatric Intensive Care Unit (PICU) and who have received continuous infusion opioids for greater
than 5 days.2,5,13,21 The WAT-1 was developed for the 2 week to 18 year range.12 Since the PICU and pediatric floors
accept and treat patients up to 21 years of age, the age inclusion criteria will be adjusted to more adequately reflect the age
population seen in the PICU, PPCU and pediatric acute care units. Numerous opioid withdrawal studies have found that
opioid tolerance may occur after 5 days of opioid exposure.5,17,22 Previous studies have found that opioid withdrawal signs
and symptoms are highest during taper days 1-6, therefore data collection will occur daily for up to 7 days.3,6,8,10,28 In order
to increase external validity, we will include all admitting diagnoses. Pediatric patients (2 weeks to 21 years) from all
ethnic and racial backgrounds will be recruited. Since one of the variables of the WAT-1 is restlessness, children with
paralysis of one or more limbs or who are receiving neuroparalytics will be excluded. Should the enrolled participant be
transferred to another pediatric unit (PPCU, M7C or M7E) during the up to 7 days of data collection, the student PI will
continue data collection on those units. Based upon the sample size and the student PIs ability to collect data on up to 4
patients per day, a data collection period of 6 months is feasible.
Methods
Measurement of major variables
1. Opioid withdrawal signs and symptoms
Known opioid withdrawal signs and symptoms in the pediatric population include gastrointestinal (diarrhea,
nausea, vomiting), autonomic (fever, sweating, mottling) and central nervous systems (tremor, agitation, frequent yawning,
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frequent sneezing, motor disturbance, hypertonia).2-6,8-11,13,18-23 Opioid withdrawal signs and symptoms will be measured
using the 11 item Withdrawal Assessment Tool – 1(WAT-1). The WAT-1 is an 11 item pediatric opioid withdrawal
instrument that includes measures of gastrointestinal (diarrhea, nausea, vomiting), autonomic ( fever, sweating) and central
nervous system (tremor, sedation state, uncoordinated movement, yawning or sneezing, startle to touch, muscle tone and
time to gain calm) measures of opioid withdrawal.13 This pediatric instrument is the revised version of the original 21 item
Opioid Benzodiazepine Withdrawal Scale (OBWS).10 The original instrument was tested in a pediatric critical care
population (n=15 patients; 693 observations) ranging in age from 6 weeks to 28 months. The result of the original testing
of the proposed 21 item OBWS (sensitivity = 50%; reliability = 87%) led to a revision of the OBWS to the 19 item WAT1. The 19 item WAT-1 was tested in a pediatric critical care population (n=83; 1040 observations) ranging in age from 6
months to 10 years. Redundant signs and symptoms and symptoms with low levels of association with withdrawal
intensity ratings were eliminated resulting in the current recommended 11 item tool.13 The WAT-1 (Appendix A) showed
superior psychometric properties (sensitivity = 87%; specificity = 88%) compared to the initial testing of the OBWS
(sensitivity = 50%; specificity= 80%; IRR=0.8). Although inclusion criteria for the validation of the WAT-1 ranged from 2
weeks to 18 years, the actual sample ranged from age 6 months to 10 years. Since the WAT-1 is validated only for the 6
month to 10 year age group, children aged <6 months or >10 years will be excluded. The WAT-1 includes the State
Behavioral Scale (SBS) which was originally validated for assessment of pre and post stimulus state (Appendix B).1 The
SBS was designed to evaluate the young patient’s response to a progressive stimulus. Negative numbers reflect levels of
sedation. Positive numbers reflect levels of agitation. A score of zero reflects neither agitation nor sedation. “The
progressive stimulus used in the SBS assessment provides a standard stimulus for observing signs of withdrawal.” 1 Since
the SBS is a subscale of the WAT-1 score, it will be completed along with each WAT-1 measurement.
2. Opioid exposure
Opioids are used routinely in the pediatric intensive care population in order to reduce pain, anxiety and morbidity.
Continuous infusion of both an opioid (fentanyl) for analgesia and a benzodiazepine (midazolam) for sedation is routine
practice in the PICU for all mechanically ventilated infants and children. Given the synergistic effects of benzodiazepines
and opioids, the addition of an opioid has been associated with up to 50% dose reductions of midazolam.29 Fentanyl is
preferred to morphine since it releases less histamine, thus decreasing the associated hypotension.19 Numerous clinical
studies have found that the duration of opioid receptor occupancy is related to the development of opioid tolerance.7,10,30,31
In a prospective study conducted by Katz et al (1994), 23 infants (<23 months) were observed for signs of opioid
withdrawal post opioid exposure.5 They found a positive correlation of dosage (p<0.005) and length of exposure (p
<0.0001) on occurrence of opioid withdrawal. In fact, a dose of 2.5mg/kg fentanyl or more than 9 days exposure was
100% predictive of withdrawal. Since withdrawal signs and symptoms may be affected by both opioid dose (cumulative
and peak) as well as duration, in this study opioid exposure will consist of all of these factors.
Opioid Dose (Cumulative and Peak). In a prospective study of infants ranging in age from 1 week to 22 months ,
Katz, Kelly & His found that a total dose of 1.5mg/kg was associated with a 50% rate of opioid withdrawal.5 Other studies
conducted in children have found a similar dose dependent relationship.4,6,17 In a prospective, multiple case study (n=27),
Ducharme and colleagues examined the effects of variable opioid taper rates on occurrence of opioid withdrawal on PICU
patients (age 0-19 years), there was a minimal correlation between opioid peak dose and occurrence of withdrawal (r =
0.34; p <0.05).4 In a prospective, descriptive opioid withdrawal study of critically ill children ( < 25 months), French and
Nocera found a significant correlation between cumulative fentanyl dose and opioid withdrawal score (r = 0.76; p<0.01).6
In a retrospective study of neonates, Arnold and colleagues found a total dose of 1.6mg/kg to be associated with the
development of opioid withdrawal.17 There was no significant difference in peak opioid dose between the neonates who
had opioid withdrawal and those infants with no signs or symptoms of opioid withdrawal. Because the literature shows
some relationship between cumulative and peak opioid dose on occurrence of opioid withdrawal, opioid dose will be
described as both cumulative and peak. Peak dose will be determined by calculation of daily opioid dose. To compare
analgesics across types, all opioids can be converted to a common drug (i.e. morphine) and reported as morphine
equivalents per kilogram (MEK). 8,21 For this study, fentanyl conversion to morphine will be calculated by the formula
10mg of IV morphine = 0.1mg IV fentanyl.32 Morphine equivalents will be divided by the patient’s body weight to
determine MEK. Peak and cumulative MEK will be calculated pretaper and daily at 10am during taper. All opioids will be
converted to morphine equivalents per kilogram (MEK). Daily dose of MEK will be calculated. The largest daily MEK
will be recorded as the peak opioid dose. Cumulative dose will be determined by summation of daily MEKs prior to
initiation of opioid taper.
Opioid Duration. Previous studies in children have found a correlation between opioid duration prior to taper with
occurrence of opioid withdrawal signs and symptoms.4-6,21 Ducharme and colleagues found a moderate association
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between opioid duration and occurrence of opioid withdrawal (r = 0.41; p<0.01).4 Katz, Kelly & Hsi found that a duration
of 5 days or more of fentanyl exposure was 50% predictive of opioid withdrawal.5 French and Nocera found a significant
correlation between duration of fentanyl exposure and opioid withdrawal score (r = 0.70; p<0.05).6 In a prospective,
repeated measures design study of critically ill children (n= 79; ages 0 to 16 years), Ista and colleagues found a significant
correlation between duration of opioid exposure and severity of opioid withdrawal (r= 0.52; p<0.001).21Opioid duration
will be calculated as the number of days of continuous or scheduled opioid exposure prior to initiating opioid taper.
Children with at least 5 days of opioid exposure will be eligible for the study.
3. Opioid taper rate
The goal of tapering opioids is to safely wean the opioid from the patient while avoiding the incidence of opioid
withdrawal. There is little empirical evidence to guide the practice of opioid tapering.4,8-10 Although some
recommendations exist in the literature, few recommended guidelines have been tested in the pediatric
population.2,4,7,8,10,30,31 Berens et al. (2006) conducted a double-blinded, randomized control trial using methadone and
found a 20% incidence of need for rescue medications to treat signs and symptoms of opioid withdrawal.2 Of those that
have been tested, no guideline was associated with a 0% incidence of opioid withdrawal signs and symptoms.4,7-10,30
A recent survey of international pediatric pain management providers conducted by Fisher found a wide variation
in opioid tapering practice (see preliminary study #1). Opioid tapering practices were divided into two categories:
conservative or aggressive. 69 % of practitioners in the study used a conservative method, defined as tapering reduction of
20% or less per day. 12 % used a more aggressive method, greater than 20% dose reduction per day. Within each category,
tapering practices varied. Reported conservative regimens ranged from 10% reductions per week to 10% every day.
Aggressive regimens varied from 30% every 2 days to 50% per day. Since rates of taper vary depending on clinician,
opioid tapering rate will be defined as percentage change in total opioid dose per day, expressed in morphine equivalent
units per kilogram (MEK) of the child’s body weight. Nonscheduled opioids that are administered will also be included in
the daily opioid tapering rate calculation. In addition, medications that may alleviate withdrawal signs and symptoms such
as benzodiazepines, α-adrenergic (clonidine, dexmedetomedine), antiemetics and antipyretics will be recorded. Although
several studies recommended opioid dose reductions ranging from 10-20% per day, none of the studies resulted in an
absence of opioid withdrawal signs and symptoms.2,4,7,10,30,31 At this point in time, there is no gold standard for opioid
tapering in children.
4. Severity of Illness Severity of illness is used to further describe the population and has been included in previous
pediatric opioid withdrawal studies.2,13,21 In a prospective, randomized trial comparing the effect of a 5 day methadone
taper versus a 10 day methadone taper on incidence and severity of opioid withdrawal, the investigators no difference in
severity of illness in either group. In the prospective psychometric evaluation of the WAT-1, severity of illness was
included only as a demographic characteristic.13 Similarly, Ista and colleagues included severity of illness only as a
demographic characteristic.21 Given the pervasive nature of opioid withdrawal signs and symptoms on multiple systems
including the central nervous system, autonomic nervous system and gastrointestinal system, a potential relationship
between severity of illness and opioid withdrawal signs and symptoms is possible. In addition, severity of illness may
impact the individual child’s need for analgesics and sedatives. To our knowledge, this study would be the first to examine
the relationship between severity of illness and frequency of signs and symptoms of opioid withdrawal. The revised
Pediatric Index of Mortality (PIM2) will be used to measure severity of illness.33 The PIM-2 (Appendix C) has been used
to measure severity of illness in cardiac surgery patients, 34 severe head injury,35 medical surgical,36 and multidisciplinary
PICU populations.37 The PIM2 will be measured, based on data from the previous 24 hours, at time of study enrollment.
5. Age. Few studies have evaluated the effect of age on opioid withdrawal signs and symptoms.5,13 Katz and colleagues
found no correlation between age and incidence of opioid withdrawal.5 Franck found some age related differences in
incidence of specific opioid withdrawal signs and symptoms.13 For example, there was a higher incidence of vomiting in
the 0-2 year age group (12.3%) compared to the >6 years age group (3.2%). Age, in months, will be measured at the time
of study enrollment.
6. Additional Demographics
Other demographic data (race, gender, hospital admission diagnosis, length of mechanical ventilation, ICU length
of stay) will be collected to describe the sample.
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Table 2:Key study variables and their measurement
Variable
Measure
Opioid withdrawal signs and
WAT-1 (0-12)
symptoms
Opioid exposure
Opioid dose
Peak opioid dose (in MEK)
Cumulative opioid dose ( in MEK)

Measurement Interval
Daily at same time for 7 days

Once at time of study enrollment
Once at time of study enrollment

Opioid duration
Opioid taper rate

Number of days of opioid exposure
opioid mg/kg per day (MEK per day)

Once at time of study enrollment
Daily for 7 days

Severity of Illness

Pediatric Index of Mortality (PIM2)

Once at time of study enrollment

Age
Additional demographic data

Age in months
Once at time of study enrollment
Race, gender, admission diagnosis,
Once at time of study enrollment –
weight in kilograms, length of
ICU LOS may not be available at time
mechanical ventilation (days), ICU
of enrollment
length of stay (days)
Note. WAT-1 = Withdrawal Assessment Tool -1. MEK = Morphine equivalents per kilogram
Procedure:
Prior to beginning the study, the student PI will provide an informational inservice to the pediatric nursing
leadership and staff of the involved units (PICU, PPCU, M7C & M7E). The student will identify patients who meet
selection criteria through daily rounds on the PICU. Since this is a descriptive study, there will be no change in the medical
plan of the participants. No more than minimal risk is anticipated. Data obtained will not affect the participant’s routine
care nor will it be used in the clinical management of opioid tapering. Waiver of assent is being requested since the
intended participants will be sedated during the observation period. Permission will be obtained from the parent/legal
guardian at time of study enrollment.
Should the child awaken during the data collection time period, the student investigator will debrief them on the
study. Data collection timing will occur each afternoon between 10 AM and 4 PM during times of routine care in order to
allow a consistent time point from the previous day’s opioid dosing changes and avoid the usually busy early morning
clinical rounds. The exact time will be negotiated with the bedside nurse in order to minimize any potential disruption of
routine care. Data collection will occur daily for up to 7 days. Decisions about individual opioid therapy for these subjects
including opioid duration and dosage will be made by the medical team.
At the time of study enrollment, the student PI will collect the following data from the electronic medical record
(EMR) and bedside flowsheet: medications received within the past 24 hours, data to calculate opioid cumulative dose (in
MEK) peak opioid dose (in MEK), and number of days of opioid exposure prior to study enrollment demographic data
(age, race, gender, admission diagnosis, PIM2, weight in kilograms)
Data collection for the opioid taper rate will occur each day for up to 7 days. The student PI will collect opioid
dose information given over the past 24 hours (8a to 8a). All opioids will be converted to MEK. The sum of the MEKs will
be recorded as the MEK/day. The MEK/day will be compared to the previous day’s MEK/day and the percentage
reductions per day will be calculated.
Data collection for the WAT-1 will begin with a review of the EMR and flowsheet for the previous 12 hours, as
per the WAT-1 instructions. The student PI will then record incidence of any symptom listed on the WAT-1 including
temperature >37.8 C, vomiting/wretching/gagging and loose/watery stools. Next, the student will observe the participant
undisturbed for 2 minutes, during which time data will be collected on several variables of the WAT-1 scale: state (SBS),
tremor, sweating, uncoordinated/repetitive movements and yawning or sneezing. Next, the student PI will observe the
patient during a progressive stimulus. The progressive stimulus will entail first calling the participant’s name in a calm
voice. If the participant does not respond, then the student PI will call the participant’s name and gently touch the arm or
leg. If the participant does not respond, the student PI will observe the patient during a planned noxious procedure such as
endotracheal suctioning or turning, which will be performed by the bedside nurse. During the 1 minute stimulus
observation, the student PI will collect data on muscle tone and startle to touch. The WAT-1will be measured similarly
daily for up to 7 days.
Should a participant transfer to the progressive (PPCU) or acute care pediatric (M7C & M7E) units, the student PI
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will continue to collect data on the new unit until either completion of 7 days of data collection or hospital discharge.

X. PLAN FOR CONTROL OF INVESTIGATIONAL DRUGS, BIOLOGICS, AND DEVICES.
For investigational drugs and biologics: IF IDS is not being used, attach the IDS confirmation of receipt of the
management plan.. See item #11 on Initial Review form.
For investigational and humanitarian use devices (HUDs): Describe your plans for the control of investigational
devices and HUDs including: (1) how you will maintain records of the product’s delivery to the trial site, the inventory
at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s); (2)
plan for storing the investigational product(s)/ HUD as specified by the sponsor (if any) and in accordance with
applicable regulatory requirements; (3) plan for ensuring that the investigational product(s)/HUDs are used only in
accordance with the approved protocol; and (4) how you will ensure that each subject understands the correct use of
the investigational product(s)/HUDs (if applicable) and check that each subject is following the instructions properly
(on an ongoing basis).
NA
XI. DATA ANALYSIS PLAN
For investigator–initiated studies.
Demographic variables will be descriptively summarized. Measures of central tendency (mean, median) and
dispersion (standard deviation, range) on continuous data, and frequency and count on categorical data will be computed as
appropriate.
The first aim of the study (specific aim #1) is to describe the signs and symptoms of opioid withdrawal (WAT-1)
in children undergoing opioid tapering. Descriptive statistics (means and standard deviations) will be used.
The second aim (specific aim #2) is to examine the relationship among the maximum opioid withdrawal signs and
symptoms (WAT-1), opioid exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure) summed to
day of maximum amount, opioid taper rate (range of percentage changes), severity of illness (PIM2) and the child’s age. In
order to account for variance of opioid choice amongst practitioners, all opioids will be converted to morphine equivalents.
Distributions of all study variables will be examined to determine the need for transformations. Multiple regression will be
performed to evaluate the relationship among opioid withdrawal signs and symptoms (WAT-1), and opioid tapering rate
(range of percentage changes), opioid exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure),
and the child’s age.

XII. DATA AND SAFETY MONITORING
• If the research involves greater than minimal risk and there is no provision made for data and safety monitoring
by any sponsor, include a data and safety-monitoring plan that is suitable for the level of risk to be faced by
subjects and the nature of the research involved.
• If the research involves greater than minimal risk, and there is a provision made for data and safety monitoring
by any sponsor, describe the sponsor’s plan.
• If you are serving as a Sponsor-Investigator, identify the Contract Research Organization (CRO) that you will be
using and describe the provisions made for data and safety monitoring by the CRO. Guidance on additional
requirements for Sponsor-Investigators is available at http://www.research.vcu.edu/irb/wpp/flash/X-2.htm
The research involves no more than minimal risk. Since this is an observational study, there will be no change in the
medical plan of the participants. Data obtained will not affect the participant’s routine care nor will it be used in the
clinical management of opioid tapering. Data will be entered into an electronic record. Access to this password protected
site will be limited to the student investigator. Data will be shared only with the investigators listed on this research plan
during monthly study meetings.

XIII. MULTI-CENTER STUDIES
If VCU is the lead site in a multi-center project or the VCU PI is the lead investigator in a multi-center project,
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describe the plan for management of information that may be relevant to the protection of subjects, such as reporting
of unexpected problems, project modifications, and interim results.

NA
XIV. INVOLVEMENT OF NON-VCU INSTITUTIONS/SITES (DOMESTIC AND FOREIGN)
1. Provide the following information for each non-VCU institution/site (domestic and foreign) that has agreed to
participate:
• Name of institution/site
• Contact information for institution/site
NA

2. For each institution, indicate whether or not it is “engaged” in the research (see OHRP’s guidance on
“Engagement of
Institutions in Research” at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html.)
NA
3. Provide a description of each institution’s role (whether engaged or not) in the human subjects research, adequacy
of the facility (in order to ensure human subject safety in the case of an unanticipated emergency), responsibilities of
its agents/employees, and oversight that you will be providing in order to ensure adequate and ongoing protection of
the human subjects. You should only identify institutions that have agreed to participate. If additional institutions
agree to participate at a later time, they must be added by amendment to the protocol.

NA
4. For each institution that is “engaged” provide an OHRP Federalwide Assurance (FWA) # if: (1) the research is not
exempt, AND (2) the research involves a DIRECT FEDERAL award made to VCU (or application for such).
NOTE: Additional guidance at http://www.research.vcu.edu/irb/wpp/flash/XVII-6.htm, and
http://www.research.vcu.edu/irb/wpp/flash/XVII-11.htm.

NA
XV. INVOLVEMENT OF INDEPENDENT INVESTIGATORS
INDEPENDENT INVESTIGATOR: an individual who is acting independently and not acting as an agent or employee of
any institution or facility while carrying out his or her duties in the research protocol. Additional guidance at
http://www.research.vcu.edu/irb/wpp/flash/XVII-15.htm.
ENGAGEMENT IN RESEARCH: An independent investigator becomes "engaged" in human subjects research when
he/she (i) intervenes or interacts with living individuals for research purposes; or (ii) obtains individually identifiable
private information for research purposes [45 CFR 46.102(d)-(f)]. See OHRP’s guidance on “Engagement of
Institutions in Research” at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html.
1. Provide a list of independent investigators.
2. For each independent investigator indicate whether or not he/she is “engaged” or “not engaged” in the research
3. For each independent investigator who is “engaged”: (1) describe his/her role with human subjects/identifiable
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human data, AND (2) describe YOUR oversight of his/her involvement.
NA
NOTE: If an independent investigator is “engaged,” and the research is (1) not exempt AND (2) involves a DIRECT FEDERAL
award made to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must directly supervise all
of the research activities, (2) agreement must follow the ORSP template, (3) IRB must agree to the involvement of the
independent investigator, AND (4) agreement must be in effect prior to final IRB approval.
XVI. HUMAN SUBJECTS INSTRUCTIONS (Be sure to use the sub-headings under A-I) – you will need to update all this
when ALL the previous sections are finalized .. I am not going to review this until all that is OK …
ALL sections of the Human Subjects Instructions must be completed with the exception of the section entitled
“Special Consent Provisions.” Complete that section if applicable.

A. DESCRIPTION
Provide a detailed description of the proposed involvement of human subjects or their private identifiable data in the
work.

Data will be obtained from the electronic medical record and direct observation of the participant. Data will include: opioid
withdrawal score (WAT-1), opioid taper rate (total dose of opioid per day in MEK), medications, pretaper peak MEK,
pretaper cumulative MEK, number of days of exposure to opioids prior to taper, age of participant, gender, race, diagnosis,
weight (for use in calculation of MEK).
The participants in this study will be observed only in this descriptive study. The observation period of 7 minutes for data
collection is anticipated to be minimally intrusive and should not affect clinical care since the timing of daily data
collection will be negotiated with the bedside nurse to be conducted during times of routine nursing care.

B. SUBJECT POPULATION
Describe the subject population in terms of sex, race, ethnicity, age, etc., and your access to the population that will
allow recruitment of the necessary number of participants. Identify the criteria for inclusion or exclusion of any
subpopulation and include a justification for any exclusion. Explain the rationale for the involvement of special cases
of subjects, such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to be
vulnerable. If you plan to allow for the enrollment of Wards of the State (or any other agency, institution, or entity),
you must specifically request their inclusion and follow guidance on Wards and Emancipated Minors in the VCU IRB
Written Policies and Procedures (specifically WPP#: XV-3) available at
http://www.research.vcu.edu/irb/wpp/flash/XV-3.htm.
Participant recruitment will occur at the Children’s Hospital of Richmond, VCU Health System campus. The 7th floor
Pediatric floor will be the site of all participant recruitment. All pediatric patients (ages 2 weeks to 21 years) who have
received continuous infusion opioids for >5 days will be included in recruitment efforts. Patients will not be excluded for
race, sex, or ethnicity. Access to the population will be facilitated by the student PI who is a Pediatric Nurse Practitioner
employed by the Children’s Hospital of Richmond. Participants will be recruited over a 6 month data collection period.
C. RESEARCH MATERIAL
Identify the sources of research material obtained from individually identifiable living human subjects in the form of
specimens, records, or data. Indicate whether the material or data will be obtained specifically for research purposes
or whether use will be made of existing specimens, records, or data.
Data will be obtained from the Electronic Medical Record (EMR), bedside flowsheet and observation. Once the data has
been entered on computer, only code numbers will be associated with all forms and materials. Only the investigators will
have access to the data. Once the participant is enrolled in the study, demographic data will be collected from the EMR.
Existing data (see list below) that is not obtained at enrollment will be obtained daily for up to7 days. Length of
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mechanical ventilator days and ICU length of stay will be calculated at discharge from the PICU. Research data (see list
below) will be obtained daily for up to7 days.
Existing data- Cerner medication orders, demographic information (age, gender, weight) , length of mechanical
ventilation days (VLOS), ICU length of stay
Research data –
Collected daily -WAT-1, opioid taper rate (total MEK per day)
Collected at time of study enrollment- calculation of PIM2, calculation of peak opioid (MEK) dose and opioid cumulative
dose (MEK) plus duration (in days) of opioid exposure prior to initiation of opioid taper.

D. RECRUITMENT PLAN
Describe in detail your plans for the recruitment of subjects including: (1) how potential subjects will be identified
(e.g., school personnel, health care professionals, etc), (2) how you will get the names and contact information for
potential subjects, and (3) who will make initial contact with these individuals (if relevant) and how that contact will
be done. If you plan to involve special cases of subjects, such as children, pregnant women, human fetuses, neonates,
prisoners or others who are likely to be vulnerable, describe any special recruitment procedures for these populations.

Participants will be recruited from a pediatric intensive care population within a 12 bed unit. Notification of ongoing study
will be provided via laminated flier in each room. Potential participants will be identified by the student investigator
through daily discussion with PICU health care professionals. The student investigator will make initial contact with the
potential participants at the time of enrollment. At the time of initial contact, the student investigator will explain the study,
answer questions and obtain permission from the parent or legal guardian.

E. POTENTIAL RISKS
Describe potential risks whether physical, psychological, social, legal, or other and assess their likelihood and
seriousness. Where appropriate, describe alternative treatments and procedures that might be advantageous to the
subjects.
Since the study is observational, there will be no change in standard of care. Breach of confidentiality and invasion of
privacy are potential risks. Likelihood of occurrence is minimal.

F. RISK REDUCTION
Describe the procedures for protecting against or minimizing potential risk. Where appropriate, discuss provisions
for ensuring necessary medical or professional intervention in the event of adverse events to the subjects. Also, where
appropriate, describe the provisions for monitoring the data collected to ensure the safety of subjects.
The bedside nurse will inform the student PI when routine care (assessments, vital signs) will be delivered, so that no
additional participant stimulation will occur. Parents or legal guardians of participants will be given a copy of the
permission form. All forms and materials will be stored in a locked cabinet in a locked room. All forms will be coded with
an assigned participant number. All data entered on computer will be linked to the participant number. Participant
identifiers will be destroyed on entering data on computer. Data analysis will be reported in aggregate.

G. ADDITIONAL SAFEGUARDS IF ANY PARTICIPANTS WILL BE VULNERABLE
Describe any additional safeguards to protect the rights and welfare of participants if you plan to involve special cases
of subjects, such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to be
vulnerable. Safeguards to protect the rights and welfare of participants might relate to Inclusion/Exclusion Criteria:
(“Adults with moderate to severe cognitive impairment will be excluded.” “Children must have diabetes. No normal
controls who are children will be used.”) Consent: (“Participants must have an adult care giver who agrees to the
participant taking part in the research and will make sure the participant complies with research procedures.”
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“Adults must be able to assent. Any dissent by the participant will end the research procedures.”) Benefit:
(“Individuals who have not shown benefit to this type of drug in the past will be excluded.”).
Legal guardians of participants must give permission for enrollment of participant in study. The student investigator has
expertise in working with young infants and children.
Exclusion criteria:
No infants less than 2 weeks of age will be included; no children older than 21 years will be included. .Since one of the
variables of the WAT-1 is restlessness, children with paralysis of one or more limbs or who are receiving neuroparalytics
will be excluded.
Since this is a descriptive study, no change in medical plan is anticipated.

H. CONFIDENTIALITY
Describe how the confidentiality of data collected as part of this project will be protected including pre-screening data
(e.g., physical controls on the data; access controls to the data; coding of data; legal controls, such as a Federal
Certificate of Confidentiality; statistical methods; or reporting methods).
Each participant will be assigned a number for this descriptive study. All data will be safeguarded by storage in a password
protected electronic file. Only the student investigator will have access. Only the researchers listed on this research plan
will be shown the data. Since the data obtained will be de-identified and the data will be reported in aggregate for the final
report and publications, it will not be possible to identify any individual participant.

I. PRIVACY
Describe how the privacy interests of subjects will be protected where privacy refers to persons and their interests in
controlling access to themselves, and assess their likely effectiveness. Identify what steps you will take for subjects to
be comfortable: (1) in the research setting and (2) with the information being sought and the way it is sought.
1. If the child is awake during data collection, the student PI will establish rapport with the participant. The student
investigator has over twenty years experience as a pediatric nurse- including over 7 years experience as a PICU
nurse.
2. All efforts to remain unobtrusive will be attempted during data collection of asleep participants
3. The student PI will collaborate with the bedside nurse on timing of data collection in order to respect the comfort
and privacy of the participant. No personal data will be collected or recorded. All data collected will be stored in a
password protected database.

J. RISK/BENEFIT
Discuss why the risks to subjects are reasonable in relation to the anticipated benefits to subjects and in relation to the
importance of the knowledge that may reasonably be expected to result. If a test article (investigational new drug,
device, or biologic) is involved, name the test article and supply the FDA approval letter.
This is not a treatment study. There are no direct benefits from participation in the study. Since this is an observational
study, no more than minimal risk is anticipated. Potential benefits of this study include addition of empirical evidence to
the sparse fund of literature on the subject of opioid tapering in children. To the best of the investigator’s knowledge, this
will be the first observational study measuring signs and symptoms and severity of opioid withdrawal in children using the
recently validated opioid withdrawal instrument – WAT-1. Predicted long term benefit of the study data will be eventual
translation of the knowledge into clinical decision-making that ensures optimal assessment based management of opioid
withdrawal in children.

K. COMPENSATION PLAN
Compensation for subjects (if applicable) should be described, including possible total compensation, any proposed
bonus, and any proposed reductions or penalties for not completing the project.
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No compensation will be offered

L. CONSENT ISSUES
1. CONSENT PROCESS
Indicate who will be asked to provide consent/assent, who will obtain consent/assent, what language (e.g., English,
Spanish) will be used by those obtaining consent/assent, where and when will consent/assent be obtained, what steps
will be taken to minimize the possibility of coercion or undue influence, and how much time will subjects be afforded
to make a decision to participate.
The parent/legal guardian will be asked to provide permission for those children <18 years of age. For those patients aged
18 to 21 years, the Legal Authorized Representative (LAR) will be approached for consent. The student PI will obtain
permission using the English language. The parent/ legal guardian will be approached for permission when the student PI
has identified that the child will meet study inclusion criteria within 24 hours. The permission will be obtained at the
bedside when possible. Explanation of the study will be provided in writing and verbally. The parent/legal guardian will be
offered a hard copy of the permission to review overnight.
Since the child will be receiving sedatives and analgesics, waiver of assent is requested.
2. SPECIAL CONSENT PROVISIONS
If some or all subjects will be cognitively impaired, or have language/hearing difficulties, describe how capacity for
consent will be determined. Please consider using the VCU Informed Consent Evaluation Instrument available at
http://www.research.vcu.edu/irb/guidance.htm. If you anticipate the need to obtain informed consent from legally
authorized representatives (LARs), please describe how you will identify an appropriate representative and ensure
that their consent is obtained. Guidance on LAR is available at http://www.research.vcu.edu/irb/wpp/flash/XI-3.htm.
NA
3. If request is being made to WAIVE SOME OR ALL ELEMENTS OF INFORMED CONSENT FROM SUBJECTS OR
PERMISSION FROM PARENTS, explain why: (1) the research involves no more than minimal risk to the subjects, (2) the
waiver or alteration will not adversely affect the rights and welfare of the subjects, (3) the research could not
practicably be carried out without the waiver or alteration; AND (4) whether or not subjects will be debriefed after
their participation. Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XI-1.htm.. NOTE: Waiver is
not allowed for FDA-regulated research unless it meets FDA requirements for Waiver of Consent for Emergency
Research (see below).
NA
4. If request is being made to WAIVE DOCUMENTATION OF CONSENT, provide a justification for waiver based on one of
the following two elements AND include a description of the information that will be provided to participants: (1) the
only record linking the subject and the research would be the consent document and the principal risk would be
potential harm resulting from a breach of confidentiality. Subject will be asked whether they want documentation
linking them with the research, and each subject’s wishes will govern; or (2) the research presents no more than
minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of
the research context. Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-2.htm
NA
5. If applicable, explain the ASSENT PROCESS for children or decisionally impaired subjects. Describe the
procedures, if any, for re-consenting children upon attainment of adulthood. Describe procedures, if any, for
consenting subjects who are no longer decisionally impaired. Guidance is available at
http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm and http://www.research.vcu.edu/irb/wpp/flash/XVII-7.htm.
NA
6. If request is being made to WAIVE THE REQUIREMENT TO OBTAIN ASSENT from children age 7 or higher, or
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decisionally impaired subjects, explain why: (1) why some or all of the individuals age 7 or higher will not be capable
of providing assent based on their developmental status or impact of illness; (2) the research holds out a prospect of
direct benefit not available outside of the research; AND/OR (3) [a] the research involves no more than minimal risk to
the subjects, [b] the waiver or alteration will not adversely affect the rights and welfare of the subjects, [c] the
research could not practicably be carried out without the waiver or alteration; AND [d] whether or not subjects will be
debriefed after their participation. Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm
1. All children participating in this study will be critically ill and on sedatives and opioids hence will not be capable to
provide assent. 3. [a]The research is an observational study that will not impact daily care of the child. [b] this waiver will
not adversely affect the rights and welfare of the child, [c] the research could not be practicably carried out without the
waiver [d] should the child awaken enough to understand, the child will be debriefed after their participation.
(1)The researcher anticipates that the children enrolled in this study will be sedated and possibly unconscious during the
initial opioid tapering efforts, thus, it would be inappropriate to approach the patient for assent. (2) no direct benefit is
anticipated for the patients during the study. (3) [a]the non-experimental descriptive and correlational research involves no
more than minimal risk to the participants [b] the waiver will not adversely affect the rights and welfare of the participants
[c] the research could not practicably be carried out without waiver [d] where applicable, subjects may be debriefed after
participation at the time the legal guardian(s) are debriefed.

7. If request is being made to waive consent for emergency research, see guidance at
http://www.research.vcu.edu/irb/wpp/flash/XVII-16.htm.
NA
8. If applicable, address the following issues related to GENETIC TESTING:
a. FUTURE CONTACT CONCERNING FURTHER GENETIC TESTING RESEARCH
Describe the circumstances under which the subject might be contacted in the future concerning further participation
in this or related genetic testing research.
NA
b. FUTURE CONTACT CONCERNING GENETIC TESTING RESULTS
If planned or possible future genetic testing results are unlikely to have clinical implications, then a statement that the
results will not be made available to subjects may be appropriate. If results might be of clinical significance, then
describe the circumstances and procedures by which subjects would receive results. Describe how subjects might
access genetic counseling for assistance in understanding the implications of genetic testing results, and whether this
might involve costs to subjects. Investigators should be aware that federal regulations, in general, require that testing
results used in clinical management must have been obtained in a CLIA-certified laboratory.
NA
c. WITHDRAWAL OF GENETIC TESTING CONSENT
Describe whether and how subjects might, in the future, request to have test results and/or samples withdrawn in
order to prevent further analysis, reporting, and/or testing.
NA
d. GENETIC TESTING INVOLVING CHILDREN OR DECISIONALLY IMPAIRED SUBJECTS
Describe procedures, if any, for consenting children upon the attainment of adulthood. Describe procedures, if any,
for consenting subjects who are no longer decisionally impaired.
NA
e. CONFIDENTIALITY
Describe the extent to which genetic testing results will remain confidential and special precautions, if any, to protect
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confidentiality.
NA
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